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Abstract 
The immunosuppressive tumor microenvironment (TME) is a major barrier to immunotherapy. Within 
solid tumors, why monocytes preferentially differentiate into immunosuppressive tumor associated 
macrophages (TAMs) but not immunostimulatory dendritic cells (DCs) remains unclear. Using multiple 
murine sarcoma models, we found that the TME induced tumor cells to produce retinoic acid (RA), which 
polarized intratumoral monocyte differentiation towards TAMs and away from DCs via suppression of DC-
promoting transcription factor Irf4. Genetic inhibition of RA production by tumor cells or pharmacologic 
inhibition of RA signaling within the TME increased stimulatory monocyte-derived cells, enhanced T cell-
dependent anti-tumor immunity and demonstrated striking synergy with immune checkpoint blockade. 
Further, an RA responsive gene signature in human monocytes correlated with an immunosuppressive 
TME in multiple human tumors. RA has been long considered as an anti-cancer agent, but our work 
demonstrates its tumorigenic capability via myeloid-mediated immune suppression and provides proof of 
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The immunosuppressive tumor microenvironment (TME) is a major barrier 
to immunotherapy. Within solid tumors, why monocytes preferentially 
differentiate into immunosuppressive tumor associated macrophages 
(TAMs) but not immunostimulatory dendritic cells (DCs) remains unclear. 
Using multiple murine sarcoma models, we found that the TME induced 
tumor cells to produce retinoic acid (RA), which polarized intratumoral 
monocyte differentiation towards TAMs and away from DCs via suppression 
of DC-promoting transcription factor Irf4. Genetic inhibition of RA production 
by tumor cells or pharmacologic inhibition of RA signaling within the TME 
increased stimulatory monocyte-derived cells, enhanced T cell-dependent 
anti-tumor immunity and demonstrated striking synergy with immune 
checkpoint blockade. Further, an RA responsive gene signature in human 
monocytes correlated with an immunosuppressive TME in multiple human 
tumors. RA has been long considered as an anti-cancer agent, but our work 
demonstrates its tumorigenic capability via myeloid-mediated immune 
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CHAPTER 1: INTRODUCTION 
1.1: Overview of cancer immunotherapy 
The infiltration of neoplastic tissue with leukocytes, first reported by Rudolf 
Virchow in the 19th century, provided initial evidence that the immune 
system may interact with cancer (Balkwill and Mantovani, 2001). Virchow 
hypothesized that “irritation” of normal tissue associated with a 
lymphoreticular infiltrate may contribute to the origin of tumors (Balkwill and 
Mantovani, 2001). We now understand that the immune system does 
indeed engage with malignant tissue, and that inadequate tumor immunity 
fundamentally contributes to the tumor progression (Motz and Coukos, 
2013). 
 
In an effort to restore immune control of cancer, a multitude of 
immunotherapy strategies have been discovered and developed over the 
years. One of the earliest attempts of cancer immunotherapy dates back 
more than 100 years to the Memorial Hospital in New York, where surgeon 
scientist William B. Coley subcutaneously injected bacterial products 
(colloquially known as “Coley’s Toxins”) into patients with sarcomas and 
other types of solid tumors to boost anti-tumor immune responses (Coley, 
1891). Although his approach was reported to demonstrate considerable 
activity in clinical trials, it was deemed at the time to have limited therapeutic 
value (van den Boorn and Hartmann, 2013). 
 
 2 
Over the past few decades, however, the scientific community has made 
significant progress in our understanding of how the immune system 
interacts with cancer (Chen and Mellman, 2013). Indeed, a strong body of 
literature demonstrates that the immune system plays an active role in 
shaping the immunogenicity of growing tumors (Schreiber and Podack, 
2009). Spontaneously induced immune responses were clearly shown by 
Schreiber and others to protect from carcinogen-induced sarcoma and 
epithelial carcinomas in mice (Dunn et al., 2004). Further, over the course 
of tumorigenesis, it is now understood that immune pressure is required to 
generate the growth of selected tumor cell clones with enhanced resistance 
to immune-mediated deletion, in part due to deficiencies in immunogenic 
antigens (Motz and Coukos, 2013). On the flip side, these studies 
emphasize the importance of tumor heterogeneity and genetic instability in 
shaping the anti-tumor immune response. Collectively, the aforementioned 
interactions in which cancer cells attempt to thrawrt immune-mediated 
clearance are termed immune evasion. The eventual failure of the immune 
response against cancer leading to tumor outgrowth has been termed 
immune escape (Dunn et al., 2004). 
 
Tumor infiltrating T cells are a hallmark of ongoing anti-tumor immune 
surveillance. Although anti-tumor T cells can be spontaneously generated 
in tumors, the sustained deletion of tumor cells which express targets of T 
cell attack enable tumors to escape T cell-mediated clearance 
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(van den Boorn and Hartmann, 2013). Nevertheless, overcoming immune 
suppressive factors in the tumor microenvironment and lymphoid organs 
has led to augmented anti-tumor T cell immune responses, suggesting the 
presence of immune evasion mechanisms beyond antigen escape in solid 
tumors (Benci et al., 2016). Along these lines, fundamental discoveries into 
the regulation and function of T cells have led to the development of an 
arsenal of T cell-based immunotherapies. Most prominently, insight into the 
negative regulation of T cell activation and effector function has led to the 
clinical development of “immune checkpoint” inhibitors in a multitude of 
cancers. These include monoclonal antibodies against programmed cell 
death protein 1 (PD-1) and cytotoxic T lymphocyte associated protein 4 
(CTLA-4).  Though the clinical success of alleviating T cell suppression by 
anti-PD-1 and anti-CTLA-4 monoclonal antibodies highlight the therapeutic 
potential of targeting immune evasion pathways for the treatment of solid 
tumors, the majority of patients demonstrate inadequate clinical responses, 
suggesting the presence of additional immune evasion mechanisms (Broz 
and Krummel, 2015). My thesis work sought to uncover additional ways in 
which tumor cells thwart the immune system and prevent immune-mediated 
control of solid tumors. In particular, my work focused on the contributions 
of myeloid cells as critical regulators of anti-tumor T cell responses. Myeloid 
cells are amongst the most abundant cell types in sarcomas and the 
majority of solid tumors. Therefore, a deeper understanding of their biology 
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in the context of tumorigenesis may provide opportunities for improved 
therapeutic approaches for the treatment of cancer. 
 
1.2: Tumor immunity cycle 
Tumor immunity involves (1) the capture and processing of tumor antigens 
by antigen presenting cells (APCs), (2) migration of APCs to draining lymph 
nodes to prime T cells, and (3) migration of primed T cells to the tumor 
where they exert cytotoxic anti-tumor effects (cytotoxic T cells or CTLs) 
(Coley, 1891). APCs are important at multiple steps of this cycle; dendritic 
cells (DCs) process tumor antigens to prime anti-tumor T cells, DCs and 
immunostimulatory (M1-polarized) tumor-associated macrophages (TAMs) 
support CTL function, while immunosuppressive (M2-polarized) TAMs 
counteract CTL function (Chen and Mellman, 2013).  
 
DCs are sentinel cells of the immune system that are required to identify 
and eliminate threats (Mildner and Jung, 2014a). While the scientific 
community has a good understanding of mechanisms by which pathogens 
activate DCs, how tumors are sensed and subsequently eliminated by DCs 
is poorly understood. Mice deficient in DCs display defects in anti-tumor 
immunity, demonstrating that DCs can detect tumors and orchestrate anti-
tumor immune responses (Fuertes et al., 2011; Hildner et al., 2008a). 
Recent studies have supported the concept that tumors can alter DC 
function or prevent DC recruitment. For example, Wnt/β-catenin activation 
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was shown in a subset of melanoma tumors to block DC and recruitment 
into the tumor microenvironment. In turn, defective DC recruitment resulted 
in a lack of cytotoxic T cell priming, poor CD8 T cell infiltration into tumor, 
and ultimately to resistance to immune checkpoint blockade  (Spranger et 
al., 2015a). Furthermore in ovarian cancer, lipid peroxidation products were 
demonstrated to activate the ER stress response pathway and thereby 
disable critical functions of DCs in the tumor bed and draining lymph node, 
such as antigen presentation (Juan R. Cubillos-Ruiz et al., 2015).  
 
The aforementioned examples serve to not only emphasize the importance 
of DCs in the generation and maintenance of anti-tumor T cell responses, 
but also to exemplify the diversity of immune evasion mechanisms that solid 
tumors may utilize. Indeed, immunosuppression within the tumor 
microenvironment (TME) has emerged as a key barrier for the 
immunotherapy of solid tumors. The TME promotes suppressive TAMs and 
inhibits DCs, thereby impeding the generation and maintenance of 
functional anti-tumor CTLs (Veglia and Gabrilovich, 2017). Therefore, 
identifying pathways that polarize APC distribution in the TME is critical for 
developing new treatment approaches for cancer immunotherapy. 
 
1.3: Mononuclear phagocyte ontogeny and heterogeneity in solid 
tumors 
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The tumor microenvironment (TME) contains two major types of antigen 
presenting cells (APCs) – tumor associated macrophages (TAMs) and 
dendritic cells (DCs). DCs are required to generate effective anti-tumor 
immunity as they process and present tumor associated antigens to initiate 
anti-tumor T cell responses (Broz and Krummel, 2015; Veglia and 
Gabrilovich, 2017). Currently, several subsets of DCs have been identified 
based on their ontogeny and dependence on specific transcription factors. 
Under steady state conditions, the vast majority of DCs in tissues develop 
from common dendritic cell precursors (CDPs), hardwired DC precursors 
that have committed to the DC fate before entering the periphery (Mildner 
and Jung, 2014b). CDPs give rise to classical dendritic cells (cDCs), which 
in tumors can be classified into two subsets: CD103+ CD11b- cDC1s 
dependent on transcription factors BATF3 and IRF8, and CD103- CD11b+ 
cDC2s dependent on IRF4 (Broz et al., 2014; Merad et al., 2013). Studies 
performed using genetically engineered mice that are deficient in cDC1s 
(BATF3 KO) or have a functional defect in cDC1 cross presentation 
(WDFY4 KO) have demonstrated that these cells are critical to the 
generation of anti-tumor CD8 T cell immunity (Hildner et al., 2008b; Theisen 
et al., 2018). However, cDCs are exceedingly rare and often dysfunctional 
in solid tumor microenvironments (Herber et al., 2010). To this end, efforts 
to augment cDC functionality have shown moderate promise in generating 
de novo adaptive anti-tumor immunity for specific tumor types (Juan R. 
Cubillos-Ruiz et al., 2015; Spranger et al., 2015b).  
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Macrophages can originate from early embryonic precursors or from 
circulating monocytes (Haldar and Murphy, 2014). Likewise, DCs 
differentiate from bone-marrow derived DC-precursors (conventional DCs 
or cDCs) or from circulating monocytes (monocyte-derived DCs or moDCs) 
(Mildner and Jung, 2014b). While cDCs are required for both spontaneous 
and therapy-induced antitumor immune responses, the role of moDCs in 
tumor immunity is less clear (Veglia and Gabrilovich, 2017). Circulating 
monocytes are vastly more abundant than cDC precursors, and under 
inflammatory conditions can readily differentiate into moDCs (Merad et al., 
2013). Within solid tumors, however, monocytes do not appear to generate 
moDCs and instead differentiate into immunosuppressive TAMs (Richards 
et al., 2012). The molecular basis for this  is largely unknown (Salmon et al., 
2019). 
 
Under inflammatory conditions such as cancer, monocytes migrate into 
peripheral tissues and can undergo local differentiation into DCs (Merad et 
al., 2013; Segura and Amigorena, 2013). Although the transcriptional 
programs and local factors that drive the differentiation of monocyte-derived 
DCs (moDCs) are likely distinct from those that drive cDCs, the specific 
transcription factors and environmental cues that control moDC 
differentiation remain unclear (Briseño et al., 2016a; Daro et al., 2000; 
Greter et al., 2012; Menezes et al., 2016; Merad et al., 2013). moDCs have 
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been shown to play important functions in anti-tumor immunity, such as 
cross-presenting tumor antigens, migrating to tumor-draining lymph nodes 
to activate T cells, and providing stimulatory signals to maintain effector T 
cell responses, among others (Kuhn et al., 2015; Kumar et al., 2016, p. 45; 
Ma et al., 2013; Mach et al., 2000; Marigo et al., 2016; Segura et al., 2013; 
Segura and Amigorena, 2013). The relative frequency moDCs has been 
correlated with CD8 T cell activation and favorable treatment responses to 
chemotherapy and immunotherapy in various mouse and human tumors 
(Kuhn et al., 2013; Marigo et al., 2016; Rich et al., 2012).  
 
However, the majority of monocytes that enter the TME undergo local 
differentiation into immunosuppressive TAMs (Noy and Pollard, 2014; Qian 
and Pollard, 2010). Indeed, circulating monocytes are a highly abundant 
immune cell type in a variety of solid tumors and have emerged as the major 
precursors for TAMs (Franklin and Li, 2016; Ginhoux and Jung, 2014; Lim 
et al., 2016; Richards et al., 2012). Immunosuppressive TAMs are abundant 
and pose a major barrier to successful tumor immunotherapy in part by 
dampening T cell effector function (Noy and Pollard, 2014; Qian and Pollard, 
2010). The polarization of APCs toward TAMs and away from DCs is 
considered an important immune evasion strategy utilized by solid tumors 
(Broz and Krummel, 2015; Vinay et al., 2015). Importantly, circulating 
monocytes enter the TME and have the ability to differentiate into TAMs or 
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DCs – however, why the majority of monocytes differentiate into TAMs and 
not DCs is largely unknown. 
 
 
Figure 1.1.1 Ontogeny of mononuclear phagocytes in the tumor 
microenvironment. Tissue macrophages can arise from either yolk-sac 
progenitors or bone-marrow-derived monocytes. Similarly, DCs can arise 
from bone marrow derived monocytes or committed pre-DC progenitors. 
 






















Recent studies have begun to elucidate the transcriptional circuitry 
controlling monocyte differentiation into distinct APC subtypes (Briseño et 
al., 2016b). As an example, the transcription factors Irf4 and MafB were 
shown to have key roles in regulating monocyte differentiation into DC vs. 
macrophage respectively (Goudot et al., 2017). However, 
microenvironmental factors that control the selective induction of these 
transcription factors to induce alternative fate commitment of monocytes 
remain to be elucidated. 
 
Tissue metabolites may play a key role in this process, as evidenced by the 
role of environmental heme in inducing the differentiation of monocytes into 
splenic iron-recycling macrophages via induction of transcription factor 
SpiC (Haldar et al., 2014). Likewise, retinoic acid (RA), a metabolite of 
vitamin A, has been previously shown to play a role in the development and 
functional specification of peritoneal macrophages via induction of 
transcription factor Gata6 (Gundra et al., 2017; Okabe and Medzhitov, 
2014). However, how tumor metabolites may impact monocyte 
differentiation into APCs is unclear. 
 
1.5: Retinoic acid synthesis and metabolism 
RA is a small molecule generated from vitamin A-derivative retinol through 
a series of enzyme-catalyzed intermediary steps  (Duester, 2008). The first 
step in RA synthesis is the oxidation of retinol to renaldehyde, and is 
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catalyzed by a group of alcohol dehydrogenase enzymes (Duester, 2008). 
The expression of these alcohol dehydrogenase enzymes is overlapping 
and wide ranging throughout almost every tissue in the human body. The 
second step of RA synthesis is the the rate limiting step, which is the 
conversion of retinaldehyde to RA via retinaldehyde dehydrogenases 
(Raldh1, 2, or 3) (Duester, 2008). These enzymes exhibit non-overlapping 
expression in tissues and are thought to play a critical role in the regulation 
of RA synthesis, although the regulation of the expression of the enzymes 
themselves is largely unknown (Duester, 2008). The oxidization and 
sybsequent degradation of RA is executed by three cytochrome P450 
enzymes, CYP26A1, CYP26B1 and CYP26C1. Similar to Raldh enzymes, 
these CYP enzymes also display non-overlapping expression and tissue 
specificity, suggesting that they may play a role in the regulation of the 
biological roles of RA (Kumar et al., 2012). 
 
1.6: Role of retinoic acid in immune system and mononuclear 
phagocytes 
RA is a powerful morphogen with well-established roles in development 
(Erkelens and Mebius, 2017). Though RA has diverse functions in both 
innate and adaptive immunity, it is generally known to promote tolerance 
via multiple immune cell types (Erkelens and Mebius, 2017). Several 
studies have examined the impact of RA on peripheral monocyte 
differentiation with conflicting conclusions. While some studies have 
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reported that RA promotes DC differentiation, others have reached the 
opposite conclusion (Jin et al., 2010; Mohty et al., 2003). Similarly, though 
RA is known to induce Foxp3+ T regulatory cells and Arg1 producing anti-
inflammatory macrophages, it has also been reported to promote anti-tumor 
Th1 or Th17 T cell responses and dampen myeloid derived suppressor cell 
function (Bhatt et al., 2014; Bhattacharya et al., 2016; Hill et al., 2008; 
Nefedova et al., 2007; Vellozo et al., 2017). Factors contributing to these 
discrepancies include the exclusive reliance on cell surface markers to 
represent cellular identity and function, the use of inconsistent or supra-
physiological doses of RA in experimentation, and the presence of 
additional environmental factors that modulate RA’s effects (Duester, 2017). 
Further, the impact of RA on tumor-associated APCs remains unclear.  
 
 
1.7: Role of retinoic acid in tumorigenesis 
Raldh enzymes are highly expressed in many human tumors (Khoury et al., 
2012; Li et al., 2010, 2014; Marcato et al., 2015; Wei et al., 2015; Zhang et 
al., 2013, p. 3). Indeed, given RA’s critical role as a pro-differentiation agent 
during development, the effect of RA to promote tumor cell differentiation 
and suppress tumor growth has been studied for decades, albeit with limited 
clinical translation outside of promyelocytic leukemia (Tang and Gudas, 
2011). However, solid tumors represent a complex niche comprising of 
many different cell types other than malignant cells (Binnewies et al., 2018). 
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Hence, we wanted to explore whether RA could act on immune cells in the 
TME to promote immune suppression and facilitate tumor growth, a concept 
that has not been adequately explored. 
 
1.8: Overview of sarcoma 
Soft tissue sarcoma (STS) is a rare but heterogeneous collection of fatal 
malignancies that arise from mesenchymal tissue such as fat, muscle, 
cartilage, etc (Blay and Ray-Coquard, 2016). Though surgery and radiation 
are mainstay therapies for localized disease, metastasis is common and 
often fatal, with metastatic STS exhibiting a 5 year survival rate of less than 
15% (Linch et al., 2014). Recent efforts to utilize immunotherapies such as 
immune checkpoint blockade in STS have demonstrated efficacy only in a 
small percentage of patients; unfortunately, the vast majority of patients 
remain refractory (Ghosn et al., 2017). Uncovering novel immune evasion 
mechanisms in STS is thus critical to develop efficacious immunotherapies 
for this fatal disease. 
 
Human sarcomas are heterogeneous with over 70 diagnostic subtypes, but 
can be broadly classified based on their underlying genetic aberrations: (1) 
unique translocations resulting in fusion oncogenes, (2) mutations in tumor 
suppressors or oncogenes and (3) genomic instability without a consistent 
mutation (Taylor et al., 2011). We utilize a representative mouse model for 
each of these genetic categories: synovial sarcoma (SS) (driven by SYT-
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SSX fusion oncogene), undifferentiated pleomorphic sarcoma (UPS) 
(driven by loss of p53 and activation of KRAS), and fibrosarcoma (FS) 
(syngeneic transplant of sarcoma cell lines derived from methylcolanthrene 
induced murine fibrosarcomas) (Haldar et al., 2007; Kirsch et al., 2007; 
Schreiber and Podack, 2009).  
 
 
Figure 1.1.2. Representative mouse models of diverse sarcomas. 
Sarcomas can be classified genetically into broad categories – those with a 
complex karyotype and sarcomas with simple genetic alterations, which are 
further subclassified into translocation-associated sarcomas or sarcomas 
with other specific mutations. We utilize representative mouse models for 






















CHAPTER 2: TUMOR-DERIVED RETINOIC ACID PROMOTES 
MACROPHAGE AND BLOCKS DENDRITIC CELL DIFFERENTIATION 
FROM INTRATUMORAL MONOCYTES 
 
2.1: TME promotes monocyte differentiation into immunosuppressive TAMs 
2.1.1: Distribution of mononuclear phagocytes in sarcoma 
The distribution, function and ontogeny of mononuclear phagocytes 
(MPs) have been described in common solid tumors such as breast, lung, 
colon and melanoma (Broz et al., 2014; Broz and Krummel, 2015; Laoui et 
al., 2011). In contrast, MPs have been sparsely studied in sarcoma 
(Ehnman and Larsson, 2015). In fibrosarcoma, undifferentiated 
pleomorphic sarcoma and synovial sarcoma mouse models, monocytes 
and TAMs comprised the majority of intratumoral leukocytes (Fig. 2.1.1A 
and 2.1.1C). In contrast, CD11b+ DCs were rare and CD103+ DCs 
exceedingly rare (Fig. 2.1.1B, 2.1.1D, 2.1.1E). These results are in 
concordance with the aforementioned studies which also concluded that 
though the frequency of leukocytes may differ based on tumor type, the 
majority of leukocytes in solid tumors are mononuclear phagocytes. Of 
mononuclear phagocytes, the vast majority are monocytes and 




Figure 2.1.1: Distribution of mononuclear phagocytes in sarcoma. A 
and B, Representative contour plots of monocyte (CD45+CD11b+Ly6C+), 
TAM (CD45+CD11b+F4/80+Ly6C-) and DC (CD45+ZBTB46+) distributions in 
FS tumors (n>20 tumors). C and D, Representative contour plots of 
monocytes, TAMs and DCs in UPS tumors (n=8 tumors). E, Representative 
contour plots of TAM and DC distribution in SS tumors (n=6 tumors). 
 
2.1.2: Ontogeny of mononuclear phagocytes in sarcoma 
Studies in other solid tumors have shown monocytes to be the major source 
of TAMs (Richards et al., 2012). However, this may depend on the type of 
solid tumor, as recent studies have suggested that yolk-sac derived 
macrophages may be the source of TAMs in pancreatic ductal 
adenocarcinoma. To identify monocyte progenies in the sarcoma TME, we 
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used monocyte lineage-tracing by generating FS tumors (syngeneic 
transplant) in LysMCre: Rosa26tdT hosts (Abram et al., 2014). LysM marks 
monocytes and neutrophil ontogeny (Abram et al., 2014). The majority of 
TAMs were indeed tdTomato positive and thus derived from monocytes in 
this setting (Fig. 2.1.2A). In contrast, monocytes generated a minor fraction 
of DCs (Fig. 2.1.2A). We further corroborated these findings in a monocyte-
deficient autochthonous mouse model of UPS generated by breeding the 
murine UPS model to Ccr2-/- mice (Fig. 2.1.2B and 2.1.2C). In Ccr2-/- mice, 
which have approximately a three-fold reduction in circulating monocytes in 
addition to a defect in monocyte egress into tissues, tumor macrophages 
(but not tumor DCs) were reduced approximately two fold, suggesting a 
monocytic origin for tumor macrophages (Fig. 2.1.2B and 2.1.2C). 
 
 
Figure 2.1.2: Ontogeny of mononuclear phagocytes in sarcoma. A, 
LysM lineage tracing. FS tumors were implanted into Lyz2Cre: LSLtdT: 
Zbtb46GFP hosts. Histogram of tdT expression in F4/80+ TAMs, CD11b+ DCs 
or CD103+ DCs. Data are representative of n>15 tumors across three 
independent experiments. B and C, Comparison of TAM, CD11b+ DC and 
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CD103+ DC frequency in Ccr2 deficient (Ccr2-/-) and control (Ccr2+/+) UPS 
tumors (n=4 tumors per group). *p<0.05, Two-tailed t test. All error bars 
represent SEM. Events shown are pregated on live singlets unless 
otherwise specified. 
 
2.1.3: Suppressive function of mononuclear phagocytes in 
sarcoma 
Though monocytes, macrophages and DCs can impact T cell function in the 
tumor microenvironment, the relative ability for each of these cell types to 
stimulate or suppress T cell responses remains unclear. To assess the 
impact of the different MP subsets on T cell proliferation we isolated 
monocytes, TAMs, or DCs from tumors and co-cultured them with aCD3/28 
stimulated splenic T cells (Fig. 2.1.3A). DC isolation was greatly facilitated 
by use of the Zbtb46GFP mouse that allowed clear distinction of DCs from 
TAMs, which can be challenging by using surface markers alone (Satpathy 
et al., 2012, p. 46). In both FS and UPS, TAMs and monocytes suppressed 
T cell proliferation, with TAMs displaying greater suppression (~2-3x) (Fig. 
2.1.3B, 2.1.3C, 2.1.3D). In stark contrast, DCs stimulated T cell proliferation 
(Fig. 2.1.3E). Hence, the abundant TAMs were the most 




Figure 2.1.3: Suppressive function of mononuclear phagocytes in 
sarcoma. A, Experimental outline of T cell suppression assay (D, E) 
performed with tumor MPs (gating scheme shown in A, B). FS flank tumors 
were established in Zbtb46-GFP hosts. At 14d post-transplant, specified 
MP populations were sorted and co-cultured for 3d with aCD3/28 stimulated 
splenic T cells obtained from non-tumor bearing hosts. T cells were labelled 
with CFSE and assayed for proliferation. B, Results of T cell suppression 
assay with tumor monocytes or TAMs (n=5 tumors, pooled). Shown are 
frequency and absolute number of proliferated CD4 and CD8 T cells. Data 
are representative of three independent experiments. C, Frequency and 
absolute number of CD44hi T cells following co-culture with Ly6C+ tumor 
monocytes or F4/80+ TAMs from FS. MPs were sorted from n=5 tumors. 
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Data are representative of three independent experiments. D, T cell 
suppression assay using MPs from autochthonous UPS. Ly6C+ monocytes 
or F4/80+ TAMs were sorted from n=3 tumors. Shown are frequency and 
absolute number of proliferated T cells. E, Frequency and absolute number 
of proliferated T cells following co-culture with DCs or TAMs (n=3 tumors, 
pooled). Data are representative of two independent experiments. *p<0.05, 
**p<0.01. One-way ANOVA with Tukey’s post hoc test. All error bars 
represent SEM. Events shown are pregated on live singlets unless 
otherwise specified. 
 
2.1.4: TME promotes intratumoral monocytes to differentiate into 
suppressive macrophages 
Our results thus far show that monocytes undergo TAM but not DC 
differentiation within TME.  Monocytes are heterogeneous with regards to 
their differentiation potential into DCs vs. macrophages (Briseño et al., 
2016b; Menezes et al., 2016; Olingy et al., 2019). Therefore, one 
explanation for the skewed monocyte differentiation within TME may be the 
selective recruitment of monocyte subsets that are primed for macrophage 
differentiation. Alternatively, factors in the TME may drive macrophage 
differentiation from “uncommitted” monocytes. To address this, we first 
isolated bulk monocytes from the bone marrow of LysMCre: Rosa26tdT: 
Zbtb46GFP mice, transplanted them into FS tumors, and analyzed their 
differentiation over time (Fig. 2.1.4A). Progenies of transplanted monocytes 
 21 
were identified by tdT fluorescence while DC and TAM differentiation was 
assessed by a combination of GFP (Zbtb46) expression and surface 
markers (Fig. 2.1.4B). In this setting, the majority of monocytes 
differentiated into TAMs, whereas a very small fraction differentiated into 
DCs (Fig. 2.1.4C). Hence, the TME appears to polarize monocyte 
differentiation toward TAMs and away from DCs. 
 
 
Figure 2.1.4: TME promotes intratumoral monocytes to differentiate 
into suppressive macrophages. A, Experimental outline of intratumoral 
monocyte transfer to track monocyte differentiation within the TME. 
Monocytes were isolated from bone marrow of Lyz2Cre: Rosa26tdT: 
Zbtb46GFP hosts using negative selection on magnetic columns (MiltenyiTM). 
5 x 105 monocytes were injected directly into FS flank tumors (7d post-
transplant). Tumors were harvested and analyzed by FCM at specified time 
points. B, Representative contour plots of tdT+ cells (derived from 
transplanted monocytes) in FS tumors at 3d or 7d post-monocyte transplant. 
C, Frequency of F4/80+ or Zbtb46-GFP+ cells within the tdT+ fraction at 
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indicated time points. Data aggregated from three independent experiments. 
Each dot represents an individual mouse. Two-tailed t test. All error bars 
represent SEM. Events shown are pregated on live singlets unless 
otherwise specified. 
 
2.1.5: Intratumoral monocytes retain capacity for dendritic cell 
differentiation 
Though the aforementioned results demonstrate that tumor monocytes 
exclusively differentiate into macrophages within the tumor 
microenvironment, it remains unexplored whether tumor monocytes still 
have the ability to differentiate into DCs. Indeed, in many other settings of 
infection and inflammation, abundant monocytes have been shown to 
generate large numbers of DCs. To ask whether intratumoral monocytes 
retain the ability to differentiate into DCs, we isolated tumor monocytes and 
cultured them ex vivo with DC promoting cytokines GM-CSF and IL-4 (Fig. 
2.1.5A and 2.1.5B). Remarkably, in this setting the vast majority of 
monocytes differentiated into DCs while a minor fraction differentiated into 
macrophages (Fig. 2.1.5C). Furthermore, we observed that the major 
subsets of circulating monocytes (Ly6Chi and Ly6Clo monocytes) are also 
present within the sarcoma TME (Fig. 2.1.5D). Taken together, these 
findings suggest that TME-associated factors promote monocyte 




Figure 2.1.5: Intratumoral monocytes retain capacity for dendritic cell 
differentiation. A, Experimental outline of tumor monocyte ex vivo DC 
differentiation system. FS flank tumors were established in Zbtb46GFP hosts. 
Ly6C+ Zbtb46-GFP- monocytes were sorted from 14d tumors and cultured 
for 3d with GM-CSF and IL-4. B, Sorting scheme to isolate tumor monocytes 
from FS tumors generated in Zbtb46GFP hosts. C, Contour plots and 
frequencies of DC and macrophage markers in tumor monocytes 
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differentiated ex vivo. Monocytes were sorted from n=8 tumors over three 
independent experiments. Each dot represents an individual mouse. D, 
Histograms depicting the frequency of Ly6Chi monocytes in mouse 
peripheral blood, FS flank tumor, and naïve lung. Cells were pregated on 
live singlets, CD45+ Ly6G- CD11b+ F4/80- CD11c- MHCII- to exclude 
neutrophils, macrophages and DCs. Histograms shown are representative 
of at least 5 independent experiments. All error bars represent SEM. Events 
shown are pregated on live singlets unless otherwise specified. 
 
2.2: Tumor cells produce retinoic acid in response to T cell derived 
Interleukin 13 
2.2.1: Sarcomas harbor elevated levels of RA 
To identify factors within the TME driving monocyte differentiation into TAMs, 
we performed microarray-based gene expression profiling of TAMs isolated 
from our murine sarcoma models. Compared to tissue resident 
macrophages, we found that TAMs expressed high levels of cellular retinoic 
acid binding proteins (CRABPs) (Fig. 2.2.1A, 2.2.1B and 2.2.1C). High 
CRABP expression was independently validated by isolating monocytes, 
macrophages, and DCs from tumors and normal tissues (Fig. 2.2.1D). 
Further, gene expression profiling of bulk tumor revealed higher expression 
of enzymes catalyzing the rate-limiting step of RA synthesis (retinaldehyde 
dehydrogenases or Raldhs) compared to surrounding normal muscle (Fig. 
2.2.1E). These unbiased transcriptomic studies suggested that sarcomas 
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may produce and respond to elevated RA. To directly quantify RA, we 
performed liquid chromatography / mass spectrometry for the major 
bioactive isoform of RA, all-trans retinoic acid (ATRA), and found elevated 
ATRA in all three mouse sarcoma models compared to normal 
mesenchymal tissues such as muscle, subcutaneous fat and endothelial 
cells (Fig. 2.2.1F). 
 
 
Figure 2.2.1: Sarcomas harbor elevated levels of RA. A, Microarray 
(Affymetrix, mouse gene 1.0ST) based gene expression profiling was 
performed on CD45+ F4/80+ CD11c- TAMs FACsorted from autochthonous 
UPS. Shown are the expression (y-axis, linear scale) of cellular retinoic acid 
binding proteins (CRABPs) in TAMs compared to selected tissue resident 
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macrophages (expression values downloaded from ImmGen database). 
LPM: large peritoneal macrophage; RPM: red pulp macrophage; MG: 
microglia. B, Relative expression of Crabp1 and Crabp2 in sorted TAMs 
(CD11b+ F4/80+) from SS tumors (n=6, pooled) compared to lung or spleen 
macrophages from non-tumor bearing mice (n=3, pooled). C, Heatmap of 
the top 50 differentially expressed genes in TAMs (microarray described in 
2A) to selected tissue resident macrophages (expression values 
downloaded from ImmGen database). LPM: large peritoneal macrophage; 
RPM: red pulp macrophage; MG: microglia. D, Relative expression of 
Crabp1 and Crabp2 in sorted monocyte (CD45+ CD11b+ F4/80- Ly6C+), 
macrophage (CD45+ CD11b+ F4/80+) and DC (CD45+ Ly6C- F4/80- CD11c+ 
MHCII+) populations from lung (n=3 mice, pooled), spleen (n=3 mice, 
pooled) or FS tumor (n=5 tumors). E, Microarray (Affymetrix mouse gene 
1.0ST) based expression of Aldh1a2 (Raldh2) in autochthonous SS 
compared to surrounding skeletal muscle. Each dot represents an individual 
mouse tumor (n=3 per group). F, Liquid chromatography / mass 
spectrometry for all-trans retinoic acid (ATRA) was performed on snap 
frozen subcutaneous adipose tissue (n=3), pelleted and snap frozen mouse 
primary lung microvascular endothelial cells (n=3), FS tumors (n=10), UPS 
tumors (n=5) or SS tumors (n=5). All expression normalized to Hprt. *p<0.05, 
**p<0.01. Two-tailed t test. (A), and (E) were analyzed with one-way 
ANOVA with Tukey’s post hoc test. All error bars represent SEM. Events 
shown are pregated on live singlets unless otherwise specified. 
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2.2.2: Tumor cells produce majority of RA in sarcoma 
To identify the cellular source of RA in the TME, we used a fluorescence-
based assay that quantitates the enzymatic activity of aldehyde 
dehydrogenases (Aldh), a larger family of enzymes which includes Raldh 
(Ginestier et al., 2009). RA production was largely restricted to tumor cells 
in all of our murine models (Fig. 2.2.2A, 2.2.2B and 2.2.2C). To assess 
whether Aldh activity in this assay was indicative of Raldh activity, we 
performed unbiased gene expression profiling on sorted Aldh+ and Aldh- 
tumor cells. Raldh transcripts were the only members of the Aldh enzymatic 
family that were upregulated (data not shown). Additionally, there was 
differential upregulation of Raldh isoforms between sarcoma subtypes, with 
synovial sarcoma upregulating Raldh2, and fibrosarcoma upregulating 
Raldh3 (Fig. 2.2.2D and 2.2.2E). Though unique regulatory mechanisms of 
the Raldh family members remain unclear, the three enzymes are thought 
to perform redundant catalytic function by oxidizing retinaldehyde to RA 
(Kumar et al., 2012). These data demonstrate that tumor cells produce the 




Figure 2.2.2: Tumor cells produce majority of RA in sarcoma. A, 
ALDERED assay was performed on mouse SS. Representative contour plot 
of eGFP+ tumors cells, CD45+ leukocytes and stromal cells (left). 
Representative histograms of ALDERED fluorescence in the 
aforementioned populations (right). “Control” samples (top) show 
ALDERED fluorescence in the presence of a potent Aldh inhibitor (DEAB) 
while “test” samples (bottom) show the same without the inhibitor, which 
allows accurate identification of fluorescence imparted by Aldh activity. Bar 
graph shows frequency of Aldh+ cells within indicated parent populations 
(n=6 tumors). B and C, ALDEFLUOR assay was performed on mouse UPS 
or FS. Shown are representative contour plots of “control” and “test” 
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samples along with frequency (bar graph) of Aldh+ cells within indicated 
parent populations (n=4 UPS and n=10 FS tumors).  D, Aldh+ or Aldh- cells 
were sorted from mouse SS (n=3) tumors. Relative expression of Raldh 
isoforms were quantified by qPCR. Normalized to Hprt expression. Data 
representative of two independent experiments. E, Aldh+ or Aldh- cells were 
sorted from mouse FS (n=5) tumors. Relative expression of Raldh isoforms 
were quantified by qPCR. Data representative of two independent 
experiments. *p<0.05, **p<0.01, ***p<0.001. Two-tailed t test. (D) and (E) 
analyzed with one-way ANOVA with Tukey’s post hoc test. All error bars 
represent SEM. Events shown are pregated on live singlets unless 
otherwise specified. 
 
2.2.3: TME is required for tumor cell RA production 
Of note, only a subset of tumor cells exhibited RA production in murine 
sarcomas. We also found that FS tumor cells massively upregulated Raldh 
in vivo compared to the in vitro cell line (Fig. 2.2.3A), prompting us to wonder 
whether RA production is induced by the TME. To further address this, we 
isolated Aldh+ (RA-producing) and Aldh- (RA-negative) tumor cells from FS 
tumors, cultured the cells separately for 7 days in vitro, and re-transplanted 
them each into syngeneic recipients (Fig. 2.2.3B). We found that Aldh+ 
tumor cells ceased to display Aldh activity when cultured in vitro (Fig. 
2.2.3C). Further, re-transplantation of Aldh+ or Aldh- cells resulted in similar 
proportions Aldh+ tumor cells in in vivo tumors (Fig. 2.2.3D). Hence, RA-
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producing tumor cells cease RA production in vitro while RA-negative cells 
regain the capacity to produce RA in vivo. These results suggest that TME-
associated factors induce tumor cells to produce high levels of RA. 
 
 
Figure 2.2.3: TME is required for tumor cell RA production. A, qPCR 
analysis of Raldh expression in FS tumor cell line in vitro compared to FS 
tumors in vivo (n=4 FS tumors). Results shown are normalized to Hprt 
expression and representative of three independent experiments. B, 
Experimental outline of RA producing vs. RA negative FS re-transplant 
experiment. Aldh+ or Aldh- cells were isolated from 14d FS tumors and 
cultured for 7d in vitro. Subsequently, in vitro cultured Aldh+ or Aldh- tumor 
cells were re-transplanted into flanks of naïve C57BL/6 hosts. C, 
ALDEFLUOR assay was performed on FS Aldh+ tumor cells that were 
sorted and cultured for 7d in vitro as described above. Shown are 
representative contour plots of “control” and “test” samples, which show 
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significant loss of Aldh activity when cultured in vitro. D, Aldh+ or Aldh- re-
transplanted tumors (as described in (G)) were harvested 14d post-
transplant and assayed by ALDEFLUOR. Frequency of ALDEFLUOR+ cells 
is shown (n= 5 tumors per group). Data are representative of two 
independent experiments. ***p<0.001. Two-tailed t test. (A) was analyzed 
with one-way ANOVA with Tukey’s post hoc test. All error bars represent 
SEM. Events shown are pregated on live singlets unless otherwise specified. 
 
2.2.4: T cell derived IL-13 promotes tumor cell RA production 
To identify the TME-associated factor that might induce RA production, we 
revisited the microarray data from Aldh+ and Aldh- tumor cells. Interleukin 
13 (IL-13) receptor alpha 2 (IL13Ra2), which is known to be strongly 
induced by IL-13 signaling (Suzuki et al., 2015), was significantly higher in 
Aldh+ cells (confirmed by qPCR in sorted ALDH+ vs ALDH- tumor cells from 
FS and UPS mouse models) (Fig. 2.2.4A). Addition of recombinant IL-13 
(and to a lesser extent IL-4) to FS and UPS mouse cancer cell lines was 
sufficient to upregulate Raldh expression (Fig. 2.2.4B). Next, because IL-13 
receptor alpha 1 (IL13Ra1) transduces IL-13 signaling (Suzuki et al., 2015), 
we generated IL13Ra1 knockout sarcoma cell lines using CRISPR-Cas9. 
Upon treatment with IL-13 in vitro, IL13Ra1 KO tumor cells did not 
upregulate IL13Ra2 and strikingly, also did not upregulate Raldh3 (Fig. 
2.2.4C). Consistent with our in vitro findings, syngeneic transplants of 
IL13Ra1 knockout tumor cells demonstrated significantly reduced Raldh3 
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in vivo (Fig. 2.2.4D). Finally, we identified T cells as the primary source of 
IL-13 in TME, while the expression of IL-13 receptors was largely restricted 
to myeloid and tumor cells (Fig. 2.2.4E). Taken together, these findings 
suggest that T cell-derived IL-13 can induce RA production by tumor cells. 
 
 
Figure 2.2.4: T cell derived IL-13 promotes tumor cell RA production. 
A, ALDH+ or ALDH- tumor cells were sorted from FS or UPS flank tumors. 
Relative expression of IL13Ra2 was quantified by qPCR (n=3 FS tumors 
individually sorted; n=5 UPS tumors pooled and sorted). B, FS or UPS 
tumor cell lines were treated in vitro with recombinant IL-4 (20ng/mL), IL-13 
(20ng/mL), or DMSO. Relative expression of Raldh1 and Raldh3 were 
quantified by qPCR. C, Cas9 Control or IL13Ra1 KO UPS cell lines were 
treated in vitro with recombinant IL-13 (20ng/mL) or DMSO. Relative 
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expression of Il13ra1, Il13ra2, Raldh1 and Raldh3 were quantified by qPCR. 
D, UPS tumors were generated in C57BL/6 hosts by subcutaneous 
implantation of Cas9 Control or IL13Ra1 KO UPS cell lines. Tumors were 
harvested 11d post-implantation and tumor cells FACsorted for qPCR 
analysis. Relative expression of Il13ra1, Il13ra2, Raldh1 and Raldh3 in 
sorted tumor cells is shown. E, Relative expression of Il13, Il13ra1 and 
Il13ra2 in sorted CD45- cells, CD11b+ myeloid cells, or CD3+ CD11b- T cells 
from orthotopic FS tumors (n=10 tumors). All expression normalized to Hprt. 
*p<0.05, **p<0.01, ***p<0.001. Two-tailed t test. (B), (C) and (E) were 
analyzed with one-way ANOVA with Tukey’s post hoc test. All error bars 
represent SEM. Events shown are pregated on live singlets unless 
otherwise specified. 
 
2.3: RA-RAR signaling promotes macrophage but suppresses DC 
differentiation from monocytes via Irf4 
2.3.1: RA inhibits DC and promotes macrophage differentiation 
from mouse and human monocytes 
Results described above show (1) high levels of RA production by sarcomas, 
(2) evidence of RA exposure in TAMs, and (3) skewed differentiation of 
monocytes into TAMs within TME. Therefore, we explored whether RA 
might impact monocyte differentiation in the TME. Though RA has been 
previously implicated as a pro-differentiation agent for myeloid derived 
suppressor cells, its precise influence on the differentiation and progeny of 
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tumor infiltrating monocytes remains unclear (Bauer et al., 2018; Nefedova 
et al., 2007). 
 
To start, we utilized a well-established assay of in vitro monocyte 
differentiation with GM-CSF and IL-4 that yields a mixture of macrophages 
and DCs (Helft et al., 2015). Addition of RA at the onset of culture 
significantly impaired DC differentiation of both murine and human 
monocytes (Fig. 2.3.1A and 2.3.1B). The in vitro doses of RA were based 
on published literature and in-house data demonstrating that plasma RA 
levels range from ~5-20 nM (Duester, 2017). These effects were 
recapitulated by RAR agonist CH55 and blocked by pan-RAR inverse 
agonist BMS493, suggesting that RA acts on monocytes via the RAR 
signaling pathway (Fig. 2.3.1C). Conversely, RA promoted macrophage 
differentiation from both mouse and human monocytes (Fig. 2.3.1D and 
2.3.1E). Interestingly, these effects of RA on monocyte differentiation were 
even more striking in a modified monocyte-DC differentiation culture 
involving GM-CSF and IL-13 (Fig. 2.3.1F and 2.3.1G). A brief 
bioinformatics-based analysis of human tumors suggested that the levels of 
IL-13 may be higher than IL-4 in many solid tumors including sarcomas (Fig. 
2.3.1H) (Suzuki et al., 2015). These findings along with our aforementioned 
observations of IL-13 inducing RA support an important role of this cytokine 




Figure 2.3.1: RA inhibits DC and promotes macrophage differentiation 
from mouse and human monocytes. A, BM monocytes were isolated 
from Zbtb46GFP mice and subsequently cultured for 3d with GM-CSF and 
IL-4. RA (100nM) or DMSO was added at Day 0. Representative contour 
plots and cumulative frequencies are shown. BM monocytes were 
harvested from n=3 mice and data are representative of five independent 
experiments. B, Human monocytes obtained from normal donors were 
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cultured for 5d with GM-CSF and IL-4. RA (20nM) or DMSO were added at 
Day 0. Representative contour plots and cumulative frequencies are shown. 
Data are representative of three independent experiments. C, Frequency of 
CD11c+ CD1a+ cells in human monocytes cultured for 5d with GM-CSF and 
IL-4 with either DMSO, RA (20nM), CH55 (RAR agonist; 10nM), BMS493 
(pan-RAR inverse agonist; 1uM) or RA + BMS493. Data are representative 
of two independent experiments. D, Representative contour plots and 
frequencies of F4/80+ cells; mouse monocytes were differentiated with GM-
CSF and IL-4 with DMSO or RA. BM monocytes were harvested from three 
Ztb46GFP mice and data are representative of five independent experiments. 
E, Frequency of CD68+ cells in human monocytes cultured for 3d with GM-
CSF and IL-4 with DMSO or RA. Data are representative of three 
independent experiments. F and G, BM monocytes were isolated from 
Zbtb46GFP mice (Miltenyi negative selection kit) and subsequently cultured 
for 3d with GM-CSF and IL-4 or GM-CSF and IL-13. RA (100nM) or DMSO 
was added at Day 0. Representative contour plots and cumulative 
frequencies are shown. BM monocytes were harvested from n=3 mice and 
data are representative of two independent experiments. H, Comparison of 
IL4 and IL13 expression (log2(RSEM+1)) expression across all TCGA 
cancer types. *p<0.05, **p<0.01, ***p<0.001. Two-tailed t test. (C), (F) and 
(G) were analyzed with one-way ANOVA with Tukey’s post hoc test. All 
error bars represent SEM. Events shown are pregated on live singlets 
unless otherwise specified. 
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2.3.2: RA inhibits DC and promotes macrophage differentiation 
from tumor monocytes 
Next, we tested whether RA also impacted the differentiation of monocytes 
that exist within tumors. We isolated tDT+ GFP- intratumoral monocytes 
from FS tumors generated in LysMCre: Rosa26tdT: Zbtb46GFP mice and 
cultured them with GM-CSF and IL-4 with or without RA. Consistent with 
results above, RA significantly inhibited DC and promoted macrophage 
differentiation from tumor monocytes (Fig. 2.3.2A, 2.3.2B and 2.3.2C). We 
also tested whether tumor-associated conditions affect RA’s ability to 
influence monocyte differentiation by culturing monocytes in vitro (with GM-
CSF + IL-4) in the presence of tumor-conditioned media. The 
aforementioned effects of RA on monocyte differentiation were significantly 
augmented in the presence of tumor-conditioned media (Fig. 2.3.2D). 
 
Finally, we tested whether tumor-derived RA can regulate monocyte 
differentiation in human cancers. Although most tumors we tested produced 
very little RA in vitro, only inducing its production in vivo as described above, 
we were able to find a human cancer cell line (hepatocellular carcinoma 
SNU398) that expressed high levels of RALDH1 in vitro (Fig. 2.3.2E). Thus, 
we co-cultured human monocytes with SNU398 in the presence or absence 
of BMS493. Consistent with our observations above, DC differentiation was 
suppressed from monocytes in the presence of SNU398. Strikingly, 
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BMS493 completely rescued this effect, suggesting that tumor-derived RA 
was largely responsible for the skewed monocyte differentiation (Fig. 
2.3.2F). Together, these results demonstrate that RA-RAR signaling inhibits 




Figure 2.3.2: RA inhibits DC and promotes macrophage differentiation 
from tumor monocytes. A - C, Ly6C+ Zbtb46-GFP- monocytes were 
isolated from FS tumors and cultured for 3d with GM-CSF and IL-4. DMSO 
or RA (100nM) was added at the onset of culture. Contour plots and 
frequencies are shown (n=3 FS tumors, data representative of three 
independent experiments). D, BM monocytes were cultured for 3d with GM-
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CSF and IL-4, in the presence or absence of 50% filtered tumor conditioned 
media from subconfluent in vitro FS cell line. RA (100nM) or DMSO was 
added at Day 0. Shown are the frequencies of CD11c+ MHCII+ DCs. E, 
Relative expression of RALDH1, RALDH2, RALDH3 in human cell lines 
HT1080 (liposarcoma), SNU398 (hepatocellular carcinoma) and PLC 
(hepatoma) in vitro culture and in vivo xenograft into NU/J hosts. 
Normalized to Hprt expression. F, Human monocytes were differentiated for 
5 days with GM-CSF and IL-4 (50ng/mL) with or without SNU398 
(hepatocellular carcinoma) cells at a 1:1 ratio. BMS493 was added at Day 
0. Shown are frequencies and absolute numbers of CD1a+ or MHCII+ cells 
at Day 5. *p<0.05, **p<0.01, ***p<0.001. Two-tailed t test. (D), (E) and (F) 
were analyzed with one-way ANOVA with Tukey’s post hot test. All error 
bars represent SEM. Events shown are pregated on live singlets unless 
otherwise specified. 
 
2.3.3: RA enhances suppressive function of mouse and human 
monocyte derived APCs 
TAMs are generally immunosuppressive while DCs are stimulatory. Hence, 
we examined whether RA affects the immunosuppressive capacity of APCs 
generated from monocytes. We co-cultured GM-CSF and IL-4 differentiated 
APCs with aCD3/28 stimulated splenic T cells and measured APC 
suppressive function by T cell proliferation and activation. As expected, the 
addition of RA during monocyte differentiation enhanced APC suppressive 
 40 
function, which was likely due to polarized monocyte differentiation towards 
suppressive macrophages and away from stimulatory DCs (Fig. 2.3.3A and 
2.3.3B). We found similar effects in an additional monocyte differentiation 
system involving GM-CSF alone (Fig. 2.3.3C and 2.3.3D). Furthermore, we 
found that RA more dramatically induces suppressive function of monocyte 
derived APCs in the presence of tumor condition media from fibrosarcoma 
(Fig. 2.3.3E). Next, to test whether RA induces additional suppressive 
capability on fully differentiated macrophages, we co-cultured aCD3/28 
stimulated T cells with mature macrophages, which were derived in vitro by 
culturing monocytes with M-CSF. Addition of RA to the macrophage T cell 
co-culture significantly increased macrophage suppressive function (Fig. 
2.3.3F and 2.3.3.G). This finding was consistent in human macrophage T 
cell co-cultures (Fig. 2.3.3H). Of note, the addition of RA to T cells in the 
absence of macrophages did not significantly impact T cell proliferation (Fig. 
2.3.3I), suggesting that the effects of RA on T cell suppression in co-cultures 
were largely mediated via macrophages. Together, these results 
demonstrated that RA polarizes monocyte differentiation towards 





Figure 2.3.3: RA enhances suppressive function of mouse and human 
monocyte derived APCs. A, BM monocytes were cultured for 3d with GM-
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CSF and IL-4. RA (100nM) or DMSO was added at Day 0. Subsequently, 
differentiated APCs were harvested, washed, and co-cultured for 3d with 
CFSE labeled aCD3/28 stimulated splenic T cells. Shown are histograms 
and frequency of proliferated T cells. Data are representative of four 
independent experiments. B, Frequency of CD44hi T cells in T cell 
suppression assay using GM-CSF and IL-4 +/- RA differentiated APCs. C, 
BM monocytes were cultured for 3d with GM-CSF alone. RA (100nM) or 
DMSO was added at Day 0. Subsequently, differentiated APCs were 
harvested, washed, and co-cultured for 3d with CFSE labeled aCD3/28 
stimulated splenic T cells. Shown are histograms and frequency of 
proliferated T cells. D, Frequency of CD44hi T cells in T cell suppression 
assay using GM-CSF alone +/- RA differentiated APCs. E, Differentiated 
APCs (from Fig. 2.3.2D tumor condition media experiment) were harvested, 
washed, and co-cultured for 3d with CFSE labeled aCD3/28 stimulated 
splenic T cells. Shown are frequencies of proliferated CD4+ or CD8+ T cells.  
F, BM monocytes were cultured for 3d with M-CSF. Subsequently, 
differentiated macrophages were harvested, washed and co-cultured for 3d 
with CFSE labeled aCD3/28 stimulated splenic T cells. RA or DMSO was 
added to the co-culture at Day 0. Shown are histograms and frequency of 
proliferated T cells. Data are representative of three independent 
experiments. G, Frequency of CD44hi T cells in T cell suppression assay 
using M-CSF differentiated macrophages (M0). RA or DMSO was added 
during macrophage T cell co-culture. H, Human monocytes obtained from 
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normal donors were cultured with M-CSF for 5d. Subsequently, 
differentiated macrophages were harvested, washed and co-cultured for 3d 
with CFSE labeled aCD3/28 stimulated T cells (freshly obtained from a 
separate human donor). RA or DMSO was added to the co-culture at Day 
0. Shown is frequency of proliferated T cells. Data are representative of two 
independent experiments. I, T cell proliferation assay in the absence of 
APCs/MPs. CFSE labeled aCD3/28 stimulated splenic T cells were cultured 
with either GM-CSF + IL-4, M-CSF or no cytokines for 3d. RA (100nM) or 
DMSO was added to each cytokine condition at Day 0. Shown is frequency 
of proliferated T cells. Data are representative of four independent 
experiments. *p<0.05, **p<0.01, ***p<0.001. One-way ANOVA with Tukey’s 
post hoc test. All error bars represent SEM. Events shown are pregated on 
live singlets unless otherwise specified. 
 
2.3.4: Irf4 is required for the effects of RA on monocyte 
differentiation 
We next sought to probe transcriptional mechanisms downstream of RA-
RAR signaling in MPs. RA is known to exert its effects on gene expression 
by binding to cognate nuclear receptors, a heterodimer of RAR/RXR 
(retinoic acid receptor/retinoid X receptor), which activate or repress 
transcription of a wide variety of genes (Duester, 2008). We performed gene 
expression profiling of mouse or human monocytes treated with RA, which 
revealed that RA induced the expression of key genes associated with 
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macrophage differentiation, while downregulating genes associated with 
moDC differentiation (Fig. 2.3.4A and 2.3.4B). 
 
Of particular interest, RA downregulated Irf4, a transcription factor known 
to regulate monocyte differentiation into DCs (Briseño et al., 2016b; 
Lehtonen et al., 2005). Therefore, we tested whether the effects of RA on 
MP differentiation are dependent on Irf4. We first confirmed by qPCR that 
RA indeed downregulated Irf4 in both mouse and human monocytes, and 
that this effect was dependent on RAR signaling (Fig. 2.3.4C and 2.3.4D). 
Further, similar to RA treated WT APCs, Irf4-deficient APCs (LysMCre: Irf4fl/fl) 
demonstrated heightened T cell suppression (Fig. 2.3.4E). Importantly, the 
addition of RA to Irf4-deficient monocytes did not further enhance 
suppressive capacity of these APCs (Fig. 2.3.4E). We also performed the 
complementary experiment of overexpressing IRF4 in human monocytes, 
which rescued RA-mediated suppression of DC differentiation (Fig. 2.3.4F). 
Taken together, these findings suggest that RA impacts monocyte 




Figure 2.3.4: Irf4 is required for the effects of RA on monocyte 
differentiation. A and B, Mouse BM monocytes from C57BL/6 mice (K), or 
human monocytes obtained from normal donors (L), were cultured with GM-
CSF and IL-4 with DMSO or RA. Cells were harvested 1d later, RNA was 
extracted, and microarray (Affymetrix Mouse Gene 2.0ST) analysis was 
performed. Shown are fold changes of selected macrophage and DC 
signature genes in RA treated compared to DMSO treated mouse or human 
monocytes. C, Mouse BM monocytes were cultured for 3d with GM-CSF 
and IL-4 with either RA, CH55 (RAR agonist), BMS493, or DMSO. RNA was 
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extracted and expression of Irf4 and Zbtb46 was measured by qPCR. 
Expression normalized to Hprt. Data are representative of two independent 
experiments. D, Human monocytes obtained from normal donors were 
cultured for 5d with GM-CSF and IL-4. RNA was extracted and expression 
of Irf4 and Zbtb46 was measured by qPCR. Expression normalized to Hprt. 
Data are representative of two independent experiments. E, Mouse BM 
monocytes were isolated from LysMCre: Irf4fl/fl or LysMCre: Irf4+/+ mice and 
cultured for 3d with GM-CSF and IL-4. RA or DMSO was added at Day 0. 
Subsequently, differentiated APCs were harvested, washed and co-
cultured for 3d with CFSE labeled aCD3/28 stimulated splenic T cells. 
Shown is frequency of proliferated T cells. Data shown are aggregated from 
three independent experiments. F, Human monocytes were transfected 
with empty plasmid (control, pMax-GFP (Lonza)) or IRF4 overexpression 
(IRF4-IRES2-eGFP (GeneCopoeia)) using Human Monocyte Nucleofector 
Kit (Lonza). 2 x 106 cells were transfected with 1ug plasmid. Expression of 
IRF4 and ZBTB46 is shown. Normalized to Hprt expression. Data are 
aggregated from 2 independent experiments with n=3 technical replicates 
per experiment.  *p<0.05, **p<0.01. One-way ANOVA with Tukey’s post hoc 
test. All error bars represent SEM. Events shown are pregated on live 




CHAPTER 3: INHIBITING RETINOIC ACID PRODUCTION OR 
RETINOIC ACID RECEPTOR SIGNALING IN THE TUMOR 
MICROENVIRONMENT AUGMENTS ANTI-TUMOR IMMUNITY 
 
3.1: Reducing tumor RA production enhances intratumoral stimulatory 
APCs 
3.1.1: CRISPR-Cas9 mediated deletion of RA producing 
enzymes 
Our data thus far show high levels of RA production by tumor cells and the 
ability of RA to promote monocyte differentiation into immunosuppressive 
TAMs. Hence, we next sought to determine the impact of decreasing tumor-
cell derived RA on the distribution and function of intratumoral APCs in vivo. 
Using CRISPR-Cas9, we generated a Raldh3 KO FS cell line, given that 
Raldh3 was specifically upregulated in RA producing FS cells in vivo. 
However, deletion of Raldh3 alone resulted in compensatory increase in 
Raldh1 expression (Fig. 3.1.1A). Thus, we generated a Raldh1/3 double KO 
(DKO) cell line, which showed >80% reduction in Raldh1 and Raldh3 
transcripts (Fig 3.1.1B), modestly reduced Aldh enzymatic activity in vivo 
(Fig. 3.1.1C), and significantly reduced ATRA levels compared to control 




Figure 3.1.1: CRISPR-Cas9 mediated deletion of RA producing 
enzymes. A, Relative expression of Raldh1 measured by qPCR in Raldh3 
single KO or Cas9 Control FS cell line. Expression normalized to Hprt. B, 
Expression of Raldh1 and Raldh3 by qPCR in Raldh1/3 DKO vs. Cas9 
Control bulk FS tumors (n=5 tumors per group harvested 11d post-
transplant). Expression normalized to Hprt. Data are representative of two 
independent experiments. C, Median fluorescence intensity of Aldh activity 
in CD45- Aldh+ cells assessed by ALDEFLUOR assay in Raldh1/3 DKO vs. 
Cas9 Control FS tumors (n=5 tumors per group harvested 11d post-
transplant). Data are representative of two independent experiments. D, 
Liquid chromatography / mass spectrometry for all-trans retinoic acid (ATRA) 
on snap frozen tissue from skeletal muscle (n=8) control FS tumors 
(parental and Cas9 controls, n=10) or Raldh1/3 DKO FS tumors (n=5). Two-
tailed t test. (B) and (D) were analyzed with one-way ANOVA. All error bars 
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represent SEM. Events shown are pregated on live singlets unless 
otherwise specified. 
 
3.1.2: Reducing tumor RA production decreases intratumoral 
suppressive macrophage and increases stimulatory DC 
DKO tumors showed reduced TAMs and increased CD11b+ DCs, while 
CD103+ DCs remained largely unchanged (Fig. 3.1.2A, 3.1.2B and 3.1.2C). 
Notably, a significantly higher fraction of F4/80+ TAMs in DKO tumors were 
CD11c+ MHCII+ and expressed higher levels of activation markers CD40, 




Figure 3.1.2: Reducing tumor RA production decreases intratumoral 
suppressive macrophage and increases stimulatory DC. A, Frequency 
of CD11b+ F4/80+ TAMs in Raldh1/3 DKO or Cas9 Control FS tumors (n=8 
tumors harvested 11d post-transplant). Data representative of three 
independent experiments. B, Frequency of CD11b+ or CD103+ DCs in 
Raldh1/3 DKO or Cas9 Control tumors (n=8 tumors harvested 11d post-
transplant). Data representative of three independent experiments. C, 
Gating strategy to identify CD11b+ DC and CD103+ DC subsets in FS 
tumors. D, Frequency of TAMs expressing both CD11c and MHCII 
(pregated on CD11b+ F4/80+) in Raldh1/3 DKO or Cas9 Control FS tumors 
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(n=8 tumors per group harvested 11d post-transplant). Data are 
representative of three independent experiments. E, Gating strategy to 
evaluate CD11c and MHCII expression on CD11b+ F4/80+ TAMs in FS 
tumors (used in Fig. 4C). F, Relative expression of Cd40, Cd86 and Tnfa in 
CD11b+ F4/80+ TAMs sorted from Raldh1/3 DKO or Cas9 Control FS 
tumors (n=5 tumors harvested 11d post-transplant). *p<0.05, **p<0.01, 
***p<0.001. Two-tailed t test. All error bars represent SEM. Events shown 
are pregated on live singlets unless otherwise specified. 
 
3.1.3: Unbiased single cell RNA sequencing of immune 
compartment in RA inhibited tumors 
We further characterized RA driven changes in intratumoral leukocytes by 
using single cell RNA-sequencing; comparing tumor-infiltrating CD45+ 
leukocytes in DKO to Cas9 Control tumors (Fig. 3.1.3A). Remarkably, the 
largest differences were observed in the myeloid compartment, with DKO 
tumors harboring reduced TAMs with immunosuppressive markers (TAM 1), 
increased TAMs with immunostimulatory markers (TAM 2), and increased 
DCs (Fig. 3.1.3B, 3.1.3C and 3.1.3D). Intriguingly, the majority of the DC 
cluster expressed Ccr2, suggesting a monocyte origin (Fig. 3.1.3B). 
Consistent with this reduction in immunosuppressive TAM by ScRNA-Seq, 
we found that F4/80+ TAMs from DKO tumors were significantly less 
suppressive to T cell proliferation and activation in vitro (Fig. 3.1.3E, 3.1.3F 
and 3.1.3G). Of note, the distribution of blood neutrophils and monocytes 
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were similar in mice harboring control or DKO tumors, suggesting that the 
effects of decreasing tumor cell RA production on immune responses are 
mostly confined to the TME (Fig. 3.1.3H and 3.1.3I). 
 
 
Figure 3.1.3: Unbiased single cell RNA sequencing of immune 
compartment in RA inhibited tumors. A, CD45+ leukocytes from 
Raldh1/3 DKO or Cas9 Control FS tumors were profiled by scRNAseq (n=4 
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tumors per group). Shown are merged tSNE plots of identified immune 
populations (left) and selected marker gene expression (right) B, Merged 
tSNE plot of reclustered myeloid populations (top) and selected marker 
gene expression (bottom). C, Density plots (top) and relative frequencies 
(bottom) of myeloid clusters in Raldh1/3 DKO or Cas9 Control tumors. D, 
Heatmap of top 15 differentially expressed genes in TAM 1 compared to 
TAM 2 myeloid populations. E, T cell suppression assay using CD11b+ 
F4/80+ TAMs sorted from Raldh1/3 DKO or Cas9 Control tumors. Sorted 
TAMs were co-cultured with CFSE labeled aCD3/28 stimulated splenic T 
cells obtained from a non-tumor bearing host. Representative histograms, 
frequencies, and absolute numbers of proliferated T cells are shown. Data 
are representative of two independent experiments. F, Sorting scheme to 
purify CD11b+ F4/80+ TAMs from FS tumors. G, Frequency of CD44hi T cells 
in T cell suppression assay using CD11b+ F4/80+ TAMs sorted from 
Raldh1/3 DKO or Cas9 Control tumors. Data are representative of two 
independent experiments. H, Frequencies of specified monocyte and 
neutrophil populations in peripheral blood of C57BL/6 hosts bearing 
Raldh1/3 DKO or Cas9 control tumors (n=5 mice per group). Data are 
representative of two independent experiments. I, Gating strategy to identify 
CD115+ peripheral blood monocyte and Ly6G+ neutrophil populations in 
C57BL/6 mice. CD115+ monocytes were further divided into Ly6Chi 
TREML4- and Ly6C- TREML4+. *p<0.05, **p<0.01, ***p<0.001. Two-tailed t 
test. (E) and (G) were analyzed with one-way ANOVA. All error bars 
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represent SEM. Events shown are pregated on live singlets unless 
otherwise specified. 
 
3.1.4: Reducing tumor RA production augments intratumoral T 
cell responses 
Additional immunophenotyping of intratumoral T cells revealed that the 
frequency of CD4+ T cells was increased in DKO tumors (Fig. 3.1.4A and 
3.1.4B). Importantly, both CD4+ and CD8+ T cells in DKO tumors produced 
significantly more IFNg compared to those from control tumors (Fig. 3.1.4C). 
Concomitant with a more stimulatory myeloid and T cell compartment, DKO 
FS demonstrated markedly decreased tumor volume and weight, which 






Figure 3.1.4: Reducing tumor RA production augments intratumoral T 
cell responses. A, Frequencies of CD4+ or CD8+ T cells within CD45+ 
leukocytes in Raldh1/3 DKO or Cas9 Control tumors (n=8 tumors per group 
harvested 11d post-transplant). Data are representative of three 
independent experiments. B, Gating strategy to identify tumor infiltrating 
CD4+ and CD8+ T cells. C, IFNg cytokine production in T cells from Raldh1/3 
DKO or Cas9 Control tumors. Intratumoral T cells were incubated with 
GolgiStop and stimulated for 4h with PMA/ionomycin. Shown are 
representative contour plots (left) and frequencies (right) of IFNg+ CD4 or 
CD8 T cells (n=5 tumors per group harvested 11d post-transplant). Data are 
representative of two independent experiments. D, Tumor growth curve of 
Raldh1/3 DKO or Cas9 Control FS tumors implanted s.c. in C57BL/6 mice. 
Tumor volume was measured every three days starting at 7d post-
implantation (n=8 tumors per group and data are representative of three 
independent experiments). E, Survival curve of mice bearing Raldh1/3 DKO 
or Cas9 Control FS tumors implanted s.c. in C57BL/6 mice (n=12 tumors 
per group and data are aggregated from three independent experiments). 
F, Tumor weight was measured in Raldh1/3 DKO or Cas9 Control tumors 
implanted s.c. into C57BL/6 mice. Tumors were harvested 16d post-
implantation (n=8 tumors per group and data are representative of three 
independent experiments). G, Tumor growth curve of Raldh1/3 DKO, 
Raldh3 single KO or Cas9 Control FS tumors implanted s.c. in C57BL/6 
mice. Tumor volume was measured every three days starting at 7d post-
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implantation (n=5 tumors per group and data are representative of two 
independent experiments). *p<0.05, **p<0.01, ***p<0.001. Two-tailed t test. 
(D), (E) and (G) were analyzed with linear mixed-effects modeling with 
Tukey’s HSD post-test or Kaplan-Meier with log-rank test. All error bars 
represent SEM. Events shown are pregated on live singlets unless 
otherwise specified. 
 
3.1.5: Additional models to validate the effects of inhibiting RA 
production on intratumoral APCs and anti-tumor immune 
responses 
The effects of Raldh1/3 DKO on immune cells and tumor size were also 
consistent in an intramuscular orthotropic transplant-based model, 
suggesting that the impact of RA deficiency is independent of the 
anatomical location of the tumor (Fig. 3.1.5A, 3.15B, 3.1.5C and 3.1.5D). 
To confirm that the observed effects in DKO tumors were driven by reduced 
RA production, we overexpressed Raldh2 in the Raldh1/3 DKO cell line to 
restore RA production (Fig. 3.1.5E). Overexpression of Raldh2 restored 
tumor growth rate in DKO FS (Fig. 3.1.5F). Correspondingly, Raldh2 
overexpression reversed the stimulatory myeloid compartment of DKO 
tumors (Fig. 3.1.5G). Together, these findings demonstrated that reducing 
tumor cell RA production engenders a stimulatory APC compartment, 




Figure 3.1.5: Additional models to validate the effects of inhibiting RA 
production on intratumoral APCs and anti-tumor immune responses. 
A, Tumor growth curve of Raldh1/3 DKO or Cas9 Control FS tumors 
implanted orthotopically into hindlimb muscle of C57BL/6 mice. Tumor 
volume was measured every three days starting at 7d post-implantation 
(n=5 tumors per group and data are representative of two independent 
experiments). B, Tumor weight was measured in orthotopic Raldh1/3 DKO 
tumors or Cas9 Control tumors (harvested at Day 13 post-implantation; n=5 
tumors per group). C, Relative expression of Cd40, Cd80, Cd86, IL1b, IFNg, 
Gzmb, Tnfa in bulk Raldh1/3 DKO tumors or Cas9 Control tumors (n=5 
tumors per group harvested 13d post-implantation) Normalized to Hprt 
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expression. Each dot represents an individual mouse tumor. D, Frequency 
of specified myeloid and lymphoid populations in Raldh1/3 DKO tumors or 
Cas9 Control tumors. E, Relative expression of Raldh2 quantified by qPCR 
in indicated FS tumors. n=5 tumors per group were harvested 14d post-
implantation. Data are representative of two independent experiments. F, 
Tumor growth curve of Raldh1/3 DKO overexpressing Raldh2-GFP (Raldh 
rescue), Raldh1/3 DKO, or Cas9 Control FS tumors implanted s.c. in Lyz2Cre: 
Rosa26-LSLCas9-IRES-GFP mice. These mice were used as hosts to minimize 
potential immune responses against Cas9 and GFP. Tumor volume was 
measured every three days starting at 7d post-implantation (n=10 tumors 
per group and data are representative of two independent experiments). G, 
Relative expression of Cd40, Cd86 and Tnfa quantified by qPCR in 
indicated FS tumors (n=5 tumors per group harvested 14d post-
implantation). Data are representative of two independent experiments. 
*p<0.05, **p<0.01, ***p<0.001. Two-tailed t test. (G) was analyzed with one-
way ANOVA with Tukey’s post hoc test. (A) and (F) were analyzed with 
linear mixed-effects modeling with Tukey’s HSD post-test or Kaplan-Meier 
with log-rank test. All error bars represent SEM. Events shown are pregated 
on live singlets unless otherwise specified. 
 
3.1.6: Reducing tumor RA production enhances T cell-
dependent anti-tumor immunity 
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We next asked whether the observed tumor growth defects with reduced 
RA production reflect tumor cell autonomous effects or anti-tumor immune 
responses. DKO tumor cells did not demonstrate a significant proliferation 
defect in vitro (Fig. 3.1.6A). Further, in contrast to the results seen in 
immunocompetent mice, depletion of either CD4+ or CD8+ T cells allowed 
for rapid growth of DKO tumors (Fig. 3.1.6B). Thus, impaired tumor 
progression upon RA reduction is dependent on CD4+ and CD8+ T cell 
immunity. Additionally, DKO tumors grew significantly faster in Batf3 KO 
mice (deficient in cDC1s) compared to WT controls, suggesting that anti-
tumor immune responses upon RA reduction required the presence of 
cDC1s which cross-present tumor antigens to prime CD8+ T cells (Fig. 
3.1.6C and 3.1.6D). 
 
Next, we sought to examine tumor-specificity of T cell responses induced 
by RA-deficiency by further engineering our Cas9-control and DKO FS cell 
lines to express the model antigen ovalbumin (OVA). We confirmed higher 
frequency and number of OVA (hence tumor)-specific splenic CD8+ T cells 




Figure 3.1.6: Reducing tumor RA production enhances T cell-
dependent anti-tumor immunity. A, In vitro proliferation assay of Raldh1/3 
DKO or Cas9 Control FS cell line. 5 x 104 cells were seeded and total 
number of live cells were measured daily for five days. B, Tumor growth 
curve following CD4+ or CD8+ T cell depletion. aCD4, aCD8 or isotype 
control antibody was administered to C57BL/6 mice starting three days 
before s.c. implantation of Raldh1/3 DKO or Cas9 Control FS tumors. 
Depleting antibodies were administered i.p. every three days. (n=5 tumors 
per group). C, Tumor growth curve of Raldh1/3 DKO or Cas9 Control FS 
tumors implanted s.c. in in Batf3-/- hosts (n=7 mice per group). D, Tumor 
weight was measured in Raldh1/3 DKO or Cas9 Control tumors implanted 
into Batf3-/- mice. Tumors were harvested at 16d post-implantation. n=7 
tumors per group. E, Raldh1/3 DKO or Cas9 Control FS tumor cell lines 
were transfected with plasmid encoding cytoplasmic OVA-ZsGreen. 3d later, 
cells were FACsorted for ZsGreen to ensure equal expression of OVA-
ZsGreen between cell lines. Subsequently, Raldh1/3 DKO OVA-ZsGreen 
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or Cas9 Control OVA-ZsGreen FS tumors were generated in C57BL/6 hosts. 
Shown are frequency and number of H-2kb/SINFEKL tetramer positive 
splenic CD8+ T cells at 11d post tumor implantation. *p<0.05, **p<0.01. 
Two-tailed t test. (A), (B) and (C) were analyzed with linear mixed-effects 
modeling with Tukey’s HSD post-test or Kaplan-Meier with log-rank test. All 
error bars represent SEM. Events shown are pregated on live singlets 
unless otherwise specified. 
 
3.1.7: Reducing tumor RA production synergizes robustly with 
immune checkpoint blockade 
Given this evidence of tumor-specific CD8+ T cell response, we tested 
whether RA reduction can synergize with PD-1 blockade for further tumor 
control. Consistent with published data, parental (control) FS were poorly 
responsive to aPD1 monotherapy (Fig. 3.1.7A) (Gubin et al., 2018). 
Strikingly, administration of aPD1 in established DKO tumors lead to 
complete tumor regression in 100% of mice (Fig. 3.1.7B and 3.1.7E). Mice 
that experienced complete regression of DKO tumors rejected re-challenge 
with parental FS but not unrelated tumor cells (Fig. 3.1.7C). Finally, 
reducing RA levels in the primary tumor (Raldh1/3 DKO) enhanced the 
sensitivity to aPD-1 in a distant (contralateral) Cas9 Control tumor, providing 
additional evidence of enhanced priming and systemic anti-tumor T cell 
immunity upon tumor RA reduction (Fig. 3.1.7D, 3.1.7E and 3.17F). 
Together, these results show that reducing tumor RA production engenders 
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a strong anti-tumor T cell response that synergizes with checkpoint 
blockade to control murine sarcoma. 
 
 
Figure 3.1.7: Reducing tumor RA production synergizes robustly with 
immune checkpoint blockade. A and B, aPD1 or isotype control antibody 
was administered to C57BL/6 mice starting 7d post-implantation of 
Raldh1/3 DKO or Cas9 Control tumors. Three doses (200ug i.p.) were given 
at Days 7, 10 and 13. Shown are tumor growth curves (A) and waterfall 
plots (B) of change in tumor volume after 12d of therapy. C, Parental FS, 
KP sarcoma, or B16-F10 melanoma tumor cell lines were implanted s.c. 
into mice that that previously experienced complete regression of Raldh1/3 
DKO tumors upon aPD1 therapy (or into naïve C57BL/6 mice as control). 
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Implantation was performed 60d after complete regression (n=10 FS, n=5 
KP, n=5 B16-F10). Shown is the survival curve for indicated groups. Mice 
were immune to re-challenge with parental FS, but not other tumors. D, 
C57BL/6 hosts were implanted with dual flank tumors: either dual Cas9 
Control tumors, or Cas9 Control and Raldh1/3 DKO tumors. Once the 
tumors were established (Day 7), aPD-1 was administered (200ug i.p. on 
Days 7, 10, 13). E, Tumor growth curves for experiment outlined in K. Tumor 
volume was measured every three days starting at 7d post-implantation 
(n=5 tumors per group). F, Frequencies of CD4+ or CD8+ T cells in Cas9 
tumors contralateral to Cas9 tumors, or Cas9 tumors contralateral to 
Raldh1/3 DKO tumors (left). Relative expression of Gzmb and Ifng in bulk 
tumors (right). Normalized to Hprt expression. *p<0.05, **p<0.01, 
***p<0.001. Two-tailed t test. (A), (C) and (E) were analyzed with linear 
mixed-effects modeling with Tukey’s HSD post-test or Kaplan-Meier with 
log-rank test. All error bars represent SEM. Events shown are pregated on 
live singlets unless otherwise specified. 
 
3.2: Inhibiting RAR signaling in TME or monocytes enhances anti-tumor 
immune responses 
3.2.1: RAR inhibition enhances intratumoral stimulatory APCs 
and T cell responses in multiple murine cancer models 
Though pharmacologic approaches to specifically inhibit Raldh enzymes 
are not available, potent antagonists of RAR signaling exist (Chiba et al., 
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2016). We first asked whether RAR signaling blockade could recapitulate 
the aforementioned effects of reducing tumor RA production. Because RAR 
antagonism has pleiotropic effects on myelopoesis and peripheral immunity, 
we restricted RA-signaling blockade to the TME via intratumoral 
administration of BMS493. This resulted in similar changes to the 
intratumoral immune compartment as observed in RA deficient DKO tumors, 
including decreased frequency of TAMs, increased activation markers on 
APCs, and increased frequency of T cells (Fig. 3.2.1A, 3.2.1B and 3.2.1C). 
Strikingly, intratumoral BMS493 robustly synergized with systemic aPD1 
therapy in FS (Fig. 3.2.1D and 3.2.1E). Of interest, Raldh1 and Raldh3 were 
significantly upregulated in tumors treated with BMS493, suggesting a 
potential resistance mechanism whereby tumors upregulate RA production 
in response to RA signaling blockade (Fig. 3.2.1F). However, administration 
of BMS493 to DKO tumors (in which this resistance mechanism cannot 
operate), did not show superior response compared to administration of 
DMSO control, suggesting the existence of additional potential resistance 




Figure 3.2.1: RAR inhibition enhances intratumoral stimulatory APCs 
and T cell responses in multiple murine cancer models. A, Frequency 
of CD11b+ F4/80+ TAMs in FS tumors treated with intratumoral BMS493 or 
DMSO. Three doses (200ug intratumorally) were given at Days 7, 10 and 
13. n=5 tumors per group were harvested 15d post-transplant. B, Relative 
expression of Cd80 and Arg1 measured by qPCR in FS tumors treated with 
intratumoral BMS493 or DMSO. Expression normalized to Hprt. (n=5 
tumors per group) C, Frequencies of CD4+ or CD8+ T cells within CD45+ 
leukocytes in FS tumors treated with intratumoral BMS493 or DMSO. (n=5 
tumors per group) D, Individual growth curves of FS tumors treated with 
aPD1 (or isotype control) in combination with intratumoral BMS493 (or 
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DMSO). BMS493 (200ug i.t.) and/or aPD1 (200ug i.p.) were administered 
at Days 7, 10 and 13. (n=5 tumors per group). E, Survival curve of mice 
bearing FS flank tumors treated with DMSO or BMS493 in combination with 
isotype control or aPD-1 antibody. Three doses of BMS493 (200ug 
intratumorally) or Isotype / aPD-1 antibody (200ug i.p.) were given at Days 
7, 10 and 13. (n=5 tumors per group). F, Relative expression of Raldh1, 
Raldh2 and Raldh3 measured by qPCR in FS tumors treated with 
intratumoral BMS493 or DMSO. Three doses (200ug intratumorally) were 
given at Days 7, 10 and 13. Expression normalized to Hprt. n=4 tumors per 
group were harvested 15d post-transplant. G, Tumor growth curves of 
Raldh1/3 DKO or Cas9 Control tumors injected intratumorally with BMS493 
or DMSO. Three doses of DMSO or BMS493 (200ug intratumorally) were 
given at Days 7, 10 and 13. Tumor volume was measured every three days 
starting at 7d post-implantation (n=5 tumors per group). *p<0.05, **p<0.01. 
Two-tailed t test. (E) was analyzed with Kaplan-Meier with log-rank test. All 
error bars represent SEM. Events shown are pregated on live singlets 
unless otherwise specified. 
 
3.2.2: RAR inhibition synergizes with immune checkpoint 
blockade selectively in RA producing tumors 
We also tested intratumoral RAR inhibition on transplanted UPS and the 
results were consistent with FS tumors in that RAR blockade synergized 
with aPD1 therapy (Fig. 3.2.2A and 3.2.2C). Notably, in contrast to our 
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findings in FS and UPS, RAR blockade did not demonstrate any effect as a 
monotherapy or in combination with aPD1 in B16-F10 melanoma, which we 
found to display little to no RA production (Fig. 3.2.2B and 3.2.2D). Together, 
these results suggested that intratumoral RAR signaling inhibition in RA-




Figure 3.2.2: RAR inhibition synergizes with immune checkpoint 
blockade selectively in RA producing tumors. A and B, Individual 
growth curves of indicated tumors treated with aPD1 (or isotype control) in 
combination with intratumoral BMS493 (or DMSO). BMS493 (200ug i.t.) 
and/or aPD1 (200ug i.p.) were administered at Days 7, 10 and 13. (n=5 
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tumors per group). C, ALDERED assay performed on transplanted UPS 
tumors. Representative contour plot of Aldh+ cells. n=5 tumors per group 
were harvested 14d post-implantation. Data are representative of two 
independent experiments. D, ALDEFLUOR assay performed on B16-F10 
melanoma tumors. n=3 tumors per group were harvested at 14d post-
implantation. Data are representative of two independent experiments. 
Events shown are pregated on live singlets unless otherwise specified. 
 
3.2.3: Additional models to validate the effects of RAR inhibition 
on intratumoral APCs and anti-tumor immune responses 
The aforementioned effects of RAR signaling inhibitors raise exciting 
translational possibilities, but were shown in syngeneic transplant-based 
systems using intratumoral injections. Hence, we next tested the effects of 
systemic delivery of BMS493 in autochthonous mouse models of SS and 
UPS. Notably, the effects of systemic BMS493 on increasing intratumoral 
stimulatory myeloid cells and T cells in these two distinct mouse models of 
sarcomas were consistent with the findings in syngeneic transplants (Fig. 




Figure 3.2.3: Additional models to validate the effects of RAR 
inhibition on intratumoral APCs and anti-tumor immune responses. A, 
Mice bearing established SS tumors (autochthonous model) were treated 
with DMSO or BMS493 i.p. (3 doses of 200ug at Days 1,3,5; mice 
euthanized on Day 7). Shown are frequencies of specified myeloid and 
lymphoid populations in SS tumors (n=3 per group). B, Relative expression 
of Cd40, Cd80, Ciita, Il1b, Tnfa in FACsorted tumor associated 
macrophages (TAMs) from DMSO or BMS493 treated SS tumors (n=3 per 
group). C, Mice bearing established UPS tumors (autochthonous model) 
were treated with DMSO or BMS493 i.p. (3 doses of 200ug at Days 1,3,5; 
mice euthanized on Day 7). Shown are frequencies of specified myeloid and 
lymphoid populations in UPS tumors (n=4 per group). D, Relative 
expression of Cd40, Ciita, Il1b, Tnfa in sorted TAMs from autochthonous 
UPS tumors in DMSO or BMS493 treated mice (n=3 per group). Each dot 
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represents an individual mouse tumor (n=4 per group). Normalized to Hprt 
expression. *p<0.05. Two-tailed t test. Events shown are pregated on live 
singlets unless otherwise specified. 
 
3.2.4: Monocyte-specific RAR inhibition increases intratumoral 
DC and augments anti-tumor immunity 
Thus far, we have shown that reducing RA in TME promotes monocyte 
differentiation into immunostimulatory APCs and enhances anti-tumor T cell 
responses. To further examine the link between these two observations, we 
devised a monocyte-transplant experiment whereby monocytes isolated 
from LysMCre: Rosa26tdT hosts were treated ex vivo with DMSO (control) or 
BMS493 (irreversible RAR blockade), washed, and transplanted into 
syngeneic FS tumors. The fate of the transplanted monocytes and their 
impact on tumor growth were monitored. In contrast to control monocytes, 
a significant fraction of BMS493 treated monocytes differentiated into 
CD11c+ MHCII+ DCs in the TME (Fig. 3.2.4A). Concomitantly, tumors 
transplanted with BMS493 treated monocytes grew at a significantly slower 
rate and displayed an immunostimulatory TME with evidence of activated 
APCs and T cells. (Fig. 3.2.4B and 3.2.4c). 
Taken together, these findings provide proof-of-concept for targeting RA-




Figure 3.2.4: Monocyte-specific RAR inhibition increases intratumoral 
DC and augments anti-tumor immunity. A, Monocytes were isolated from 
bone marrow of Lyz2Cre: Rosa26tdT hosts using negative selection on 
magnetic columns (MiltenyiTM). Monocytes were treated with either DMSO 
or BMS493 (1uM) for one hour and washed twice in PBS. Subsequently, 5 
x 105 monocytes were injected directly into FS flank tumors (three injections; 
7d, 9d and 11d post- transplant). Shown are representative contour plots of 
tdT+ cells (derived from transplanted monocytes) and frequencies of 
CD11c+ MHCII+ within the tdT+ fraction at 13d post tumor implantation. B, 
Tumor growth curve of FS tumors injected with DMSO or BMS493 treated 
monocytes. Tumor volume was measured every three days starting at 7d 
post-implantation (n=4 tumors per group and data are representative of 
three independent experiments). C, Relative expression of Cd40, Cd86, 
Ciita, Tnfa, Ifng, Gzmb in bulk FS tumors transplanted with either DMSO or 
BMS493 treated monocytes. Normalized to Hprt expression. *p<0.05, 
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**p<0.01. Two-tailed t test. (B) was analyzed with linear mixed-effects 
modeling with Tukey’s HSD post-test. All error bars represent SEM. Events 
shown are pregated on live singlets unless otherwise specified. 
 
3.3: Human tumors display evidence of RA-mediated immunosuppression 
3.3.1: Tumor cells upregulate RA producing enzymes in human 
sarcomas 
The data from murine models suggested that increased tumor RA 
production or heightened RA signaling in MPs can promote tumor immune 
evasion and contribute to poor clinical outcomes. Levels of RA producing 
enzymes are known to be elevated in many human cancers (including 
breast, lung, colon, prostate) and have been associated with poor response 
to therapy and worse survival (Khoury et al., 2012; Li et al., 2010, 2014; 
Marcato et al., 2015; Wei et al., 2015; Zhang et al., 2013, p. 3). We found 
that human UPS expressed higher levels of RALDH3 compared to non-
malignant skeletal muscle (Fig. 3.3.1A). Consistent with murine UPS, 
ALDEFLUOR analysis of human UPS showed that a subset of CD45- cells 
produced the majority of RA (Fig. 3.3.1B). This finding was corroborated in 
human SS tumors, in which CD45- cells expressed significantly higher 




Figure 3.3.1: Tumor cells upregulate RA producing enzymes in human 
sarcomas. A, Relative expression of RALDH1, RALDH2 and RALDH3 
measured by qPCR in human UPS compared to human gastrocnemius 
muscle. Expression normalized to Hprt. Each dot represents tissue sampled 
from a different location of tumor (two tissue samples from n=3 tumors). B, 
ALDEFLUOR assay on primary human undifferentiated pleomorphic 
sarcoma (UPS). Shown are histograms of “control” and “test” samples 
pregated on CD45+ (left) or CD45- cells (right). Representative of n=2 
human UPS. C, Relative expression of RALDH1, RALDH2 and RALDH3 
measured by qPCR in sorted CD45+ compared to CD45- cells from primary 
human synovial sarcoma (SS). Expression normalized to Hprt. 
Representative of n=2 human UPS. *p<0.05. Two-tailed t test. All error bars 
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represent SEM. Events shown are pregated on live singlets unless 
otherwise specified. 
 
3.3.2: Analysis of RA production across the TCGA mRNA 
dataset 
Further, analysis of The Cancer Genome Atlas (TCGA) mRNA data 
revealed that RALDH isoforms are expressed in many types of cancers with 
RALDH1 and RALDH3 generally being more highly expressed than 
RALDH2 (Fig 3.3.2A). Expression of RALDH1 or RALDH3 was significantly 
negatively correlated with survival in multiple types of human cancer (Fig. 
3.3.2B). In sarcoma, subcategorization by Raldh expression was not 
predictive of poor clinical outcome, but interpretation of these analyses is 
significantly hampered by small sample sizes and heterogeneity in sarcoma 




Figure 3.3.2: Analysis of RA production across the TCGA mRNA 
dataset. A, Comparison of ALDH1A1, ALDH1A2 and ALDH1A3 expression 
(log2(RSEM+1)) expression across all TCGA cancer types. B and C, 
Kaplan-Meier curves showing overall survival partitioned by primary tumor 
RALDH1 or RALDH3 expression in indicated cancer types using TCGA 
mRNA datasets. READ: rectum adenocarcinoma; KIRC: kidney renal clear 





3.3.3: Generation and analysis of “RA response score” in 
sarcoma 
We next wanted to probe whether high levels of RA may drive myeloid 
mediated immunosuppression in human cancer. To do this, we generated 
an unbiased list of RA regulated genes from a microarray-based RA-treated 
human monocyte gene expression profile (Fig. 3.3.3A). Subsequently, we 
queried for the expression of these genes in the TCGA mRNA database 
and determined an “RA response score” for individual tumor samples. In 
TCGA sarcoma dataset, we found that the RA score clustered uniquely 
within certain sarcoma subtypes, with DDLPS, UPS and MFS having higher 
average RA scores compared to STLMS, ULMS and SS (Fig. 3.3.3B and 






Figure 3.3.3: Generation and analysis of “RA response score” in 
sarcoma. A, List of human monocyte RA regulated genes that were used 
to build the “RA response score.” B, Heatmap of z-scores of human 
monocyte RA regulated genes (n=132; y-axis) for each tumor sample 
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(n=259; x-axis) in TCGA SARC (sarcoma) dataset. SARC dataset was 
further subcategorized into STLMS (soft tissue leiomyosarcoma), ULMS 
(uterine leiomyosarcoma), DDLPS (dedifferentiated liposarcoma), UPS 
(undifferentiated pleomorphic sarcoma), MFS (myxofibrosarcoma) and SS 
(synovial sarcoma). Human monocyte RA regulated gene list was obtained 
by analyzing microarray data of human monocytes cultured with GM-CSF 
and IL-4 treated with RA (20 nM) vs DMSO. RA regulated gene list contains 
genes that were 1) 3-fold up or down regulated after 24h of RA treatment 
and 2) were present in TCGA mRNA dataset with a median FPKM 
value >0.5. Z-score for each gene was calculated based on mean FPKM 
expression across all tumor samples. C, Box plots of “RA response score” 
for samples in SARC TCGA dataset (grouped as described in D). “RA 
response score” for each tumor sample was calculated by summing over 
the z-score for all RA regulated genes. 
D, Kaplan-Meier curves showing overall survival partitioned by RA score 
(RA high (top quartile), RA mid (middle quartiles) RA low (bottom quartile) 
in indicated sarcoma types using TCGA mRNA datasets. SARC: sarcoma, 
ULMS (uterine leiomyosarcoma), MFS (myxofibrosarcoma), DDLPS 
(dedifferentiated liposarcoma). Analyzed using Kaplan-Meier with log-rank 
test.  
 
3.3.4: Analysis of “RA response score” across TCGA mRNA 
dataset 
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Further, the RA score (compared to a “random score”) was enriched in a 
group of samples across all cancer types in TCGA, suggesting that a subset 
of human tumors experience heightened RA signaling (Fig. 3.3.4A). We 
next asked whether the RA score correlates with expression of orthogonal 
genes that are known to promote immunosuppression in solid tumors. As 
expected, the RA score was significantly correlated with RALDH3 
expression, providing transcriptional evidence that tumors that produce 
more RA also respond to higher levels of RA (Fig. 3.3.4B). Importantly, we 
found that the RA score was significantly correlated with multiple members 
of TGF  and IL-10 signaling pathways, which are known to direct potent 
immunosuppressive axes in cancer and other settings of inflammation (Fig. 
3.3.4B). We found that this association between RA score and TGF  and 
IL-10 signaling was not restricted to sarcoma, but was consistent across a 
multitude of more common epithelial-derived human cancers including 
breast invasive carcinoma, lung adenocarcinoma and colon 
adenocarcinoma (Fig. 3.3.4B). Together, these analyses suggested that 
multiple types of human solid tumors produce and respond to high levels of 




Figure 3.3.4: Analysis of “RA response score” across TCGA mRNA 
dataset. A, Comparison of “RA response score” to a “random response 
score” in all TCGA cancer types showing heterogeneous distribution of “RA 
response score.” “RA response score” was computed from the human 
monocyte RA regulated gene set (n=132 genes), while the “random 
response score” was computed from a randomly generated gene set 
(n=132 genes, varying across cancer types) following methods described 
Materials and Methods. B, “RA response score” plotted against FPKM 
values for each tumor sample for the indicated genes. Detailed explanation 
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of calculations and methodologies can be found in Materials and Methods. 
Pearson’s correlation analysis was used to determine r and p values. BRCA: 
breast invasive carcinoma; LUAD: lung adenocarcinoma; COAD: colon 
adenocarcinoma. Individual p-value for each correlation is listed in Figure 7. 
All error bars represent SEM. 
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CHAPTER 4: DISCUSSION 
4.1: Targeting myeloid differentiation in the tumor 
microenvironment 
Solid tumors possess an immunosuppressive TME that prevents both 
spontaneous and treatment-induced anti-tumor immune responses. 
Myeloid cells are key drivers of this immunosuppressive TME and pathways 
underlying myeloid immunosuppressive behavior have begun to be 
elucidated. In this context, the majority of studies have focused on pathways 
driving dysfunction of specific myeloid subsets within tumors. Some 
examples include PI3Kγ signaling driving anti-inflammatory function of 
TAMs, lipid accumulation driving tumor DC dysfunction, and prostaglandin 
E2 driving suppressive neutrophil functions (Juan R. Cubillos-Ruiz et al., 
2015; Kaneda et al., 2016; Veglia et al., 2019). Here, we describe an RA-
dependent mechanism of altered myeloid differentiation that promotes an 
immunosuppressive TME and tumor immune escape. Previous work has 
demonstrated the importance of the transcription factors Mafb and Irf4 in 
controlling monocyte fate commitment into macrophages and DCs 
respectively (Goudot et al., 2017). Our work suggests that tumors target this 
transcriptional circuitry to increase TAMs and reduce DCs. Hence, 
repolarizing the immune TME from a suppressive to stimulatory milieu may 
require targeting pathways driving both dysfunction and differentiation of 
myeloid cells in the TME. It is important to note that monocytes represent 
an abundant precursor for both TAMs and DCs. Indeed, monocytes and 
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macrophages are among the most abundant cell type in the majority of solid 
tumors. The intratumoral monocyte pool is frequency replenished by the 
infiltration of circulating monocytes from peripheral blood. Though it is likely 
that not all monocytes that egress into the tumor microenvironment have 
the potential to generate stimulatory professional antigen presenting cells, 
we show in the current study that a significant portion of intratumoral 
monocytes retain the capacity to differentiate into bonafide dendritic cells, if 
exposed to the appropriate DC inducing conditions. Hence, therapeutic 
targeting of monocyte differentiation into stimulatory DCs within the TME 
may break immunosuppressive barriers and enable immunotherapy of solid 
tumors. Indeed, we provide proof of concept for this approach by 
simultaneously targeting both RA signaling and immune checkpoints on T 
cells to achieve strong synergism. Building on these findings, we envision a 
multi-pronged approach for solid tumor immunotherapy by: (1) increasing 
tumor DCs while reducing suppressive TAMs by targeting RA signaling, (2) 
increasing availability of tumor antigens to DCs by inducing tumor cell death 
with conventional therapy (cytotoxic or radiation), and (3) overcoming T cell 
dysfunction via immune checkpoint blockade. 
 
4.2: Dual functions of retinoic acid in tumorigenesis 
RA is a well-studied signaling molecule and a powerful morphogen. 
Decades of research into RA-mediated transcriptional regulation have 
highlighted its important role in various cells types during development, 
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homeostasis, and disease. Solid tumors represent a complex niche 
comprising of many different cell types besides malignant cells. Hence, the 
overall impact of RA signaling on solid tumors is likely a sum total of its 
effects on the constituent cells of the TME. It is important to note that high 
expression of RA producing enzymes, retinaldehyde dehydrogenases 
(Raldhs) has been reported in many types of solid tumors. Even more, the 
expression of these enzymes has been correlated with poor survival in 
human cancers (Khoury et al., 2012; Li et al., 2010, 2014; Marcato et al., 
2015; Wei et al., 2015; Zhang et al., 2013, p. 3). However, RA has been 
shown to have “pro-differentiation” effects on several types of tumor cells 
and hence can be considered anti-tumor in this context. Indeed, this has 
been the dominant theme in the field of RA cancer research, as all trans 
retinoic acid is a powerful therapeutic agent for acute promyelocytic 
leukemia. The therapeutic effect of RA in this setting is likely imparted by 
the specific biology driven by the translocation driven event resulting in 
constitutive expression of the RA receptor. In contrast to the pro-
differentiation / anti-tumor effects of RA, we show here that RA drives anti-
inflammatory effects in immune cells and can be considered pro-tumor in 
this context. We focused in this study on the effects of RA on intratumoral 
myeloid cells, given that they appeared to mediate the majority of RA’s 
effects on tumor immunity in our model, and given that RA is well known to 
have a short diffusion gradient and likely acts in a paracrine manner. 
However, it is possible that RA also directly impacts anti-tumor T cells, as 
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RA has been shown before to control T cell activation, differentiation and 
effector function. Further, tumor derived RA may impact the biology of tumor 
draining lymph nodes, which remains to be explored.  
 
Nevertheless, targeting RA signaling for tumor therapy requires a clear 
understanding of its role in specific tumor types as well as selective 
targeting of the appropriate cell type within the TME. Our data suggests that 
inhibition of RA production in tumor cells, and inhibition of RAR signaling in 
myeloid cells may be effective translational approaches. Though potent 
commercially available compounds to specifically inhibit RA synthesis do 
not exist, there are inhibitors to inhibit the parent family of aldehyde 
dehydrogenase enzymes (e.g. Citral). One can also envision an in vivo 
gene editing approach to delete RA producing enzymes in human tumors, 
given that an effective delivery method exists. In terms of inhibiting RAR 
signaling, it is exciting to imagine the possibility of delivering RAR inhibitors 
such as BMS493 specifically to myeloid cells, such as tumor associated 
macrophages. In this regard, it may be possible to utilize lipid or polymer-
based compounds (such as lipid nanoparticles) as delivery vehicles for RAR 
inhibitors.  
 
We have attempted to identify tumor types where the RA-dependent 
myeloid pathway may play a role in immune evasion by computing a 
monocyte “RA response score”. The overarching intent is to identify 
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appropriate patient populations for potential clinical trials based on RA-
targeting for tumor immunotherapy. It is important to note that the “RA 
response score” was generated by treating normal donor human monocytes 
with RA. To probe the specificity of the RA response score, it may be useful 
to treat cancer cells with RA and query the expression of differentially 
expressed genes in human mRNA datasets. The hypothesis here is that the 
transcriptional response of human cancer cells to RA is significantly 
different from that of human monocytes, and ultimately may help to 
disentangle the effects of RA on the immune vs tumor cell compartments in 
solid tumors. Thinking more translationally, it may eventually be useful to 
determine a “monocyte specific” and “tumor cell specific” RA response 
score for individual patients, a balance of which may determine the scientific 
rationale and clinical efficacy of RA blockade in human cancer. 
 
4.3: Ontological specificity of metabolic control of differentiation 
DCs can originate from “hardwired” HSC-derived DC precursors (cDCs) or 
from monocytes (moDCs). In this study, we primarily focused on the effects 
of RA on moDCs given that monocytes are vastly more abundant than 
dedicated DC precursors and because monocytes continuously infiltrate 
solid tumors to differentiate into immunosuppressive TAMs. Furthermore, 
precursors of cDCs are thought to have already committed to the cDC 
lineage prior to entering the tissue microenvironment. Nonetheless, 
previous studies have examined the role of RA on splenic and intestinal 
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cDC development, finding that RA can actually promote the development of 
cDC2s (Klebanoff et al., 2013). Though outside the scope of the current 
manuscript, we also observed that RA did not suppress cDC development 
in FLT3 culture systems, in which we cultured mouse bulk bone marrow for 
7 days with FLT3. Though RA did not suppress DC development as 
assessed by Zbtb46-GFP expression, RA did induce detectable 
transcriptional and protein level changes in DC activation markers such as 
CD40, CD80 and CD86 (data not shown). This was in contrast to the effects 
of RA we observed on moDC development when using GM-CSF or GM-
CSF and IL-4 culture systems. These seeminly opposing findings of the 
effects of RA may highlight the fact that the effects of RA on DCs may 
depend on ontogeny. This is an intriguing concept with implications for 
tumor immunotherapy, and we are currently examining the contextual 
relevance and molecular basis for this selective impact of RA on DC lineage. 
 
4.4: Varied roles of Th2 cytokines in solid tumor biology 
An intriguing observation in our studies was the induction of tumor cell RA 
production by IL-13 in the TME. It is interesting to note that the related Th2 
cytokine IL-4, also induced tumor cell RA production but to a lesser extent. 
Many previous studies have shown a link between Th2 cytokine milieu and 
immunosuppressive TME, although the underlying pathways are not fully 
understood (Fridman et al., 2012; McCormick and Heller, 2015; Suzuki et 
al., 2015; Zou, 2005). Our findings provide a mechanistic explanation for 
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this observation. Most of the literature involving Th2 cytokines in tumor 
immunology focus on the roles of these cytokines on immune cells such as 
T cells or myeloid cells.  
 
Notably, both IL-4 and IL-13 play a role in the differentiation of monocytes 
into DCs and M2-polarized macrophages. Indeed, the well-established in 
vitro differentiation system to generate DCs from bone marrow monocytes 
involves the use of GM-CSF and IL-4. Induction of tumor cell RA production 
via these cytokines blocks DC differentiation while allowing M2 
macrophages to develop from monocytes, which represents an interesting 
pathway by which tumor cells sense and respond to ‘immune pressure’. 
This may represent a novel immune mechanism by which tumor cells 
prevent the formation of stimulatory APCs and thereby thwart anti-tumor T 
cell resposnes. However, it is very likely that there are other factors besides 
these cytokines that regulate RA production in solid tumors. One factor that 
we have briefly tested is hypoxia, which is known to be associated with 
immunosuppression and tumorigenesis. However, in vitro hypoxia 
treatment with 2% oxygen did not induce RA production in fibrosarcoma 
cells (data not shown). Further, it is also unclear whether tumor cells are the 
only RA-producing cells within the TME of all tumor types. Though we found 
that almost all of the RA is produced by tumor cells in sarcoma, given the 
pro-differentiation effects of RA, other non-malignant cells of TME, such as 
fibroblasts, may be the primary source of RA in some types of tumors. We 
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anticipate future work to provide further clarity into these questions, which 
will help optimize efforts to develop therapeutic approaches targeting RA 
signaling for tumor immunotherapy. 
 
In summary, our study identifies an RA-dependent immune evasion 
pathway in solid tumors, provides proof of concept for targeting this pathway 
for solid tumor immunotherapy, and describes a method to potentially 
identify human tumors in which this pathway is active and hence amenable 
to RA-targeted therapeutic approaches. 
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Figure 4.1.1: Unifying model of findings described in Devalaraja et al. 
2020. Within the tumor microenvironment, T cells produce the cytokine IL-
13, which induces tumor cells to produce retinoic acid. Retinoic acid 
production by tumor cells alters the differentiation trajectory of intratumoral 
monocytes. Retinoic acid promotes immunosuppressive macrophage but 
inhibits immunostimulatory DC differentiation from intratumoral monocytes. 
Mechanistically, retinoic acid suppresses Irf4, a transcription factor that is 
required for monocyte to DC differentiation. Macrophages promote tumor 
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growth, whereas DCs enhance anti-tumor T cell immunity. In summary, 
tumor cell production of retinoic acid represents a novel immune evasion 




CHAPTER 5: MATERIALS AND METHODS 
5.1: Experimental models and subject details: 
5.1.1: Mouse models 
Tumor models: Two GEMMs were used in these studies: Rosa26syt-ssx: 
Catnblox(e3) mice (generated as previously described(Barrott et al., 2015)) 
and KrasG12D: Trp53flox mice (a generous gift from David Kirsch)(Kirsch et 
al., 2007). Oncogenesis was initiated by local injection of Cre protein (TAT-
Cre, Millipore) in the hind limb musculature to minimize immune response 
to virus. Syngeneic fibrosarcoma flank tumors were established in C57BL/6 
mice purchased from Jackson Laboratories. 
Mononuclear phagocyte models: Zbtb46GFP mice were a generous gift 
from Kenneth Murphy(Satpathy et al., 2012, p. 46). Ccr2-/- mice were 
obtained from Jackson Laboratories and bred to KrasG12D: Trp53flox mice. 
LysMCre mice were obtained from Jackson Laboratories and bred to 1) 
Rosa26LSL-tdT 2) Irf4flox or 3) Rosa26Cas9-eGFP mice. Batf3-/- mice were 
obtained from Jackson Laboratories and/or bred in house for experimental 
use. 
Sex (both male and female) and aged matched mice between 6-8 weeks 
were used for these studies. Mice were bred and maintained in specific 
pathogen free facilities at the University of Pennsylvania. All animal 
procedures were conducted according to National Institutes of Health 
guidelines and approved by the Institutional Animal Care and Use 
Committee at the University of Pennsylvania. 
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5.1.2: Tumor cells 
C57BL/6 syngeneic fibrosarcoma cell line was a generous gift from Robert 
Schrieber at Washington University in St. Louis and was used for 
experimentation as previously described(Gubin et al., 2018). KrasG12D: 
Trp53flox sarcoma cell line was a generous gift from Sandra Ryeom and 
B16-F10 melanoma cell line was a generous gift from Andy Minn. Tumor 
cell lines were cultured in DMEM with 10% FBS, 1% Pen/Strep and 2mM 
glutamine. Low passage (<P15) cell lines were used for in vitro and in vivo 
experimentation. All cells were confirmed to be negative for mycoplasma 
contamination as assessed by MycoAlert Mycoplasma Detection Kit 
(Lonza). 
 
5.1.3: Human samples 
Human undifferentiated pleomorphic sarcoma, synovial sarcoma, or non-
malignant muscle samples were obtained from surgically resected tumors 
from patients (de-identified) undergoing therapeutic surgical resection in 
accordance with protocol approved by the Institutional Review Board at the 
University of Pennsylvania. Single cell suspensions from human tumor 
samples were generated using methods described in sections below. 
Similarly, ALDEFLUOR assay, cell sorting and qPCR analyses were 
performed as described below. 
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5.2: Method details: 
5.2.1: “RA response score” computation and TCGA analysis 
(a) RA response gene signature: We performed differential expression 
analysis, using DESeq2 (10.1186/s13059-014-0550-8), on microarray data 
of human monocytes treated with RA or DMSO. Genes up or down-
regulated by at least three-fold (with false discovery rate q-value <0.05) 
were collected and assigned to the RA response gene signature that 
contained a total of 146 genes. For analysis of TCGA mRNA datasets, only 
genes that were expressed with a FPKM value >0.5 across all patient 
samples in a cancer group were retained. This reduced the total number of 
genes in the RA response gene signature to n=132 for the SARC, BRCA, 
LUAD, and COAD datasets. 
(b) Cancer and patient specific RA response score: From the TCGA 
mRNA expression data, we computed the FPKM z-score for the n=132 RA 
response signature genes and hierarchically ranked them as shown in Fig. 
7D. The RA response score for every patient sample, in a given cancer, for 
a given gene set, was taken to be the z-score summed over all genes. In 
order to evaluate the heterogeneity in the RA response score, we also 
computed a random response score employing a randomly generated gene 
set (n=132 genes) as described above. To identify the genes in a specific 
cancer that may be regulated by the RA response score, we performed a 
genome-wide correlation between the patient RA response score and the 
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corresponding FPKM values and quantified the degree of correlation using 
a linear regression model.  
Additionally, Kaplan-Meier analyses based Raldh mRNA substratification in 
selected TCGA datasets was performed using UALCAN(Chandrashekar et 
al., 2017). High expression indicates the top quartile, while low expression 
indicates the bottom quartile. 
 
5.2.2: Analysis of microarray 
Microarray services were provided by the UPENN Molecular Profiling 
Facility, including quality control tests of the total RNA samples by agilent 
bioanalyzer and nanodrop spectrophotometry. All protocols were conducted 
as described in the Affymetrix WT Pico Reagent Kit Manual and the 
Affymetrix GeneChip Expression Analysis Technical Manual. Gene 
expression data were normalized and values modeled using ArrayStar4 
(DNASTAR). The unprocessed data for microarray reported in this 
manuscript are being deposited in GEO. 
 
5.2.3: Implantation of tumor cells, tumor growth measurements 
and survival analyses 
Cultured tumor cells were detached using 0.05% trypsin (GIBCO), washed 
once with DMEM media and once with 1x PBS, and counted in preparation 
for implantation. Tumor cells were propagated in vitro for two passages prior 
to implantation and injected cells were greater than 90% viable. 1 x 106 
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tumor cells were implanted subcutaneously (s.c.) into shaved flanks of 
recipient mice. Tumor dimensions were measured using a caliper starting 
at Day 7 and every three days thereafter; volume was calculated by using 
formula (ab2)π/2, where a is the longest measurement and b is the shortest. 
Tumor volumes of 1000mm3 were used as endpoints for survival analyses. 
Waterfall plots were generated by comparing tumor volume at the start of 
treatment to tumor volume 11d later. For re-challenge experiments with 
tumor cell lines, tumor cells were injected into mice cured of primary tumors 
for >60 days. 
 
5.2.4: Flow cytometry of murine samples 
Tumors were harvested and minced at indicated time points post-
implantation for analysis. Single cell suspensions were generated by 
digestion with collagenase B and DNAse I for 45 minutes at 37oC and 
filtration through 70uM cell strainer. Mouse blood was collected in EDTA 
tubes and RBCs were lysed using ACK lysing buffer. Samples were 
incubated for 5 minutes at room temperature with anti-mouse CD16/32 Fc 
Block, and subsequently stained on ice with primary-fluorophore conjugated 
antibodies for identification of cell populations by FACS. 7AAD (BioLegend) 
was used for dead cell discrimination. Flow cytometry was performed on an 
LSR II Flow Cytometer (BD Biosciences) and analyzed using FlowJo 
software (Treestar). List of antibodies can be found in table above. 
 
 98 
5.2.5: T cell IFNg ex vivo assay 
Single cell suspensions generated from mouse tumors were incubated for 
4 hours at 37oC with PMA (50ng/mL; Sigma), Ionomycin (750ng/mL; Sigma) 
and GolgiStop (5ug/mL; BD). Intracellular staining was performed using a 
fixation/permeabilization kit (eBiosciences) according to manufacturer’s 
instructions. 
 
5.2.6: In vitro tumor cell proliferation assay 
After tumor cells were propagated for two weeks in vitro, 5 x 104 of indicated 
tumor cell lines were plated in triplicate. Viable and non-viable cell numbers 
were counted each day for five days. 
 
5.2.7: ALDEFLUOR assay 
The ALDEFLUOR assay (STEMCELL Technologies) was performed 
according to manufacturer’s instructions to identify cells with Aldh activity. 
In brief, single cell suspensions generated from indicated tumors were 
incubated with a fluorescently tagged substrate of the Aldh enzyme; the 
fluorescent product accumulates in cells proportional to their Aldh activity. 
DEAB, a potent inhibitor of Aldh, was used as a negative control for each 
sample. Cells were subsequently stained with surface antibodies and 
fluorescence was quantified by flow cytometry. Gates for Aldh+ cells were 
drawn relative to baseline fluorescence as determined by DEAB negative 
control. To avoid spectral overlap, ALDERED assay (STEMCELL 
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Technologies) was performed in lieu of ALDEFLUOR assay for samples 
with endogenous GFP fluorescence. 
 
5.2.8: Cell sorting 
Cells were sorted on MoFlo Astrios or FACS Jazz at the Children’s Hospital 
of Philadelphia (CHOP) Flow Cytometry Core Laboratory. For 
measurement of gene expression in sorted cells, RNA was isolated from 
sorted cell pellets and qPCR performed as described elsewhere. For T cell 
suppression assays, tumor APCs were sorted into complete RPMI media 
and T cell suppression assay performed as described elsewhere. 
 
5.2.9: LC-MS for ATRA 
All-trans retinoic acid was extracted from snap frozen mouse tumors or 
normal muscle as described(Kane et al., 2008). Quantification of ATRA was 
performed by the Children’s Hospital of Philadelphia Metabolomics Core 
using liquid chromatography tandem mass spectrometry (LC-MS). 
 
5.2.10: Bone marrow monocyte isolation 
Monocytes were isolated from bone marrow of indicated mice using the 
Mouse BM Monocyte Isolation Kit (Miltenyi Biotec) according to 
manufacturer’s instructions. Viability and purity of negative selection 
monocyte isolation was assessed by flow cytometry to be >90%. 
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5.2.11: Intratumoral monocyte transfer 
Monocytes were isolated (as described above) from mouse bone marrow 
of LysMCre: Rosa26tdT: Zbtb46GFP mice. Subsequently, 5 x 105 monocytes 
were resuspended in 50uL 1x PBS and injected directly into established FS 
flank tumors at 7 days post implantation. Tumors were harvested at 
specified time points and analyzed by flow cytometry to track tdT+ monocytic 
progeny. 
 
5.2.12: In vitro and ex vivo mouse and human monocyte 
differentiation assays 
Mouse monocytes (isolated from bone marrow or sorted from LysMCre: 
Rosa26tdT: Zbtb46GFP tumors) were cultured with GM-CSF (20ng/mL) & IL-
4 (20ng/mL), GM-CSF & IL-13 (20ng/mL), GM-CSF alone, or M-CSF alone 
(20ng/mL). Normal donor human monocytes (obtained the Human 
Immunology Core at the University of Pennsylvania were cultured with GM-
CSF (50ng/mL) & IL-4 (50ng/mL), or M-CSF (50ng/mL). Murine or human 
cytokines were purchased from PeproTech. RA (100nM for mouse and 
20nM for human monocytes) or DMSO was added at specified time points 
for indicated differentiation assays. Cellular identity and function of 
differentiated monocytes was assessed by a combination of unbiased 
transcriptional analyses, flow cytometry based protein analyses, and 
functional T cell suppression assays. 
 
 101 
5.2.13: Mouse and human T cell suppression assays 
Mouse splenic T cells were isolated from a non-tumor bearing C57BL/6 
mouse using Pan T Cell Isolation Kit (Miltenyi Biotec). Viability and purity of 
negative selection T cell isolation was assessed by flow cytometry to 
be >95%. Normal donor human T cells were obtained from the Human 
Immunology Core at the University of Pennsylvania. 8 x 104 mouse or 
human T cells were labeled with CFSE and cultured for 3 days at 37oC with 
2uL of aCD3/28 beads (Dynabeads Mouse or Human T-Activator CD3/28, 
Gibco) along with 30U recombinant human IL-2. Mononuclear phagocytes 
generated under various in vitro differentiation conditions (or sorted from 
mouse tumors) were co-cultured with stimulated T cells. T cell proliferation 
and activation was measured by flow cytometry to quantify mononuclear 
phagocyte suppressive ability. 
 
5.2.14: Depletion of CD4+ or CD8+ T cells in vivo 
200ug of clone GK1.5 (CD4+ T cell depletion), clone 2.43 (CD8+ T cell 
depletion), or clone LTF-2 (isotype control) antibody was administered i.p. 
starting three days prior to tumor implantation and repeated every three 
days until mouse sacrifice. All antibodies were purchased from BioXCell. 
CD4+ and CD8+ depletion was confirmed in peripheral blood and within 
tumors by flow cytometry. 
 
5.2.15: In vivo reagents 
 102 
200ug of aPD1 monoclonal blocking antibody (clone RMP 1-14, BioXCell) 
or isotype control antibody (clone 2A3, BioXCell) was administered i.p. at 
Days 7, 10 and 13 post tumor implantation. 200ug of BMS493 (Torcis) was 
administered intratumorally at Days 7, 10 and 13 post tumor implantation. 
BMS493 was dissolved in 10uL DMSO and diluted to a final volume of 50uL 
in 1x PBS for intratumoral injection. As a vehicle control, 10uL DMSO in a 
final volume of 50uL was injected intratumorally. 
 
5.2.16: RNA isolation and qPCR analysis for gene expression 
Total RNA was isolated using GenElute Mammalian Total RNA Miniprep Kit 
(Sigma). Reverse transcription was performed using High Capacity RNA to 
cDNA Kit (Life Technologies). qRT-PCR was performed using ViiA7 Real-
Time PCR machine and TaqMan probes used for gene specific 
amplification (purchased from ThermoFisher Scientific) are listed below. 
Arg1 (Mm00475988_m1), Hprt (Mm03024075_m1), Tnfa 
(Mm00443258_m1), Il1b (Mm00434228_m1), Cd40 (Mm00441891_m1), 
Cd80 (Mm00441891_m1), Cd86 (Mm00444543_m1), Raldh1 
(Mm00657317_m1), Raldh2 (Mm00501306_m1), Raldh3 
(Mm00474049_m1), Irf4 (Mm00516431_m1), Zbtb46 (Mm00511327_m1), 
Raldh1 (Hs00946916_m1), Raldh2 (Hs00180254_m1), Raldh3 
(Hs00167476_m1), Irf4 (Hs01056533_m1), Zbtb46 (Hs01008168_m1), 
Hprt (Cat #4333768). 
 
 103 
5.2.17: CRISPR mediated gene deletion in tumor cells 
LentiCRISPRv2 vector was a gift from Feng Zhang (Addgene plasmid 
#52961). In brief, the vector was transfected into 293T cells using 
polyethylenimine (PEI) along with lentivirus packaging plasmids. Lentivirus 
supernatant was collected 48 hours later and passed through a 40uM filter. 
Subsequently, tumor cells were transduced and selected on 3ug/mL of 
puromycin for two weeks. Clones were generated using single cell sorting 
and knockout efficiency determined by genomic sequencing and gene-
specific qPCR analysis. CRISPR sequences were identified using mouse 
Geckov2 library (Feng Zhang): Raldh1: TAA-ATC-CGA-CAA-GTA-TGC-AT; 
Raldh3: TAC-TTA-CAG-CCA-GGA-TCG-CT; IL13Ra1: GAG-ACG-CTC-
AAA-TTC-GTC-AC. In vivo knockout efficiency of Raldh1/3 DKO cell line 
was determined by qPCR for Raldh1 and Raldh3 gene expression in bulk 
tumor tissue, by ALDEFLUOR assay measuring functional enzymatic 
activity on tumor single cell suspension, and by liquid chromatography / 
mass spectrometry for all-trans retinoic acid in tumor tissue. 
 
5.2.18: Overexpression of target genes in tumor cells 
Raldh2-GFP ORF expression clone was purchased from GeneCopoeia 
(Cat # EX-Mm21038-M61) and transfected into Cas9 Control or Raldh1/3 
DKO FS cell lines using electroporation and nucleofection (Amaxa 
Nucleofector II, Lonza). After three days, cell lines were sorted based on 
GFP expression using a BD FACS Jazz instrument and subsequently 
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cultured for two weeks in vitro prior to s.c. implantation. In vivo confirmation 
of overexpression was determined by qPCR for Raldh2 and maintenance 
of GFP expression in bulk tumor tissue. 
 
5.2.19: Single cell sequencing preparation 
Cas9 Control or Raldh1/3 DKO tumors (n=4 per group) were harvested on 
Day 11 (as described elsewhere) and CD45+ live cells were FACS sorted. 
Subsequently, 10x Genomics Controller and the v3 Library and Gel Bead 
kit (10x Genomics) were used to obtain single-cell emulsions. 10x 3’ v3 kit 
protocol was followed as described to generate RNA sequencing libraries. 
The generated libraries were sequenced using an Illumina NovaSeq SP. 
 
5.2.20: Single cell RNA sequencing analysis 
Downstream analysis of the single-cell RNA-sequenced samples was 
performed using Seurat (v. 3.1.0) in R (v. 3.6.0) (CITE SEURAT). Genes 
expressed in less than three cells were removed. Cells that expressed less 
than 500 genes or had over 14% mitochondrial content were filtered out. 
The four samples were merged and counts for all genes were log2 
normalized and scaled (NormalizeData and ScaleData). Principal 
components (PCs) were determined using the 2000 most variable genes 
(FindVariableFeatures). Subsequently, the top 50 PCs were used for graph-
based cluster identification and dimensionality reduction by t-distributed 
stochastic neighbor embedding (t-SNE). Myeloid clusters were subsetted 
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out using Adgre1, Lyz2, S100a9, Itgax and negative for lymphoid markers 
and re-analyzed as described above. Genes separating TAM_1 and TAM_2 
clusters were determined using the default Wilcoxon Rank Sum test in the 
FindMarkers function. 
 
5.2.21: Quantification and statistical analysis 
Statistical significance was calculated between two groups by student’s 
unpaired t test. One-way ANOVA with Tukey’s HSD post-test was used to 
calculate statistical significance between multiple groups. Significance for 
survival was calculated by Kaplan-Meier with long-rank analysis. Analyses 
were performed using GraphPad Prism 8. Error bars represent SEM and p 
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